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Abstract 
Over the last quarter century, protein microarray technology has emerged as a 
prominent field in scientific study.  The versatility of the platform, coupled with the 
ability to characterize thousands of proteins in a parallel and high-throughput manner, has 
resulted in great strides in our knowledge database.   
Many clinical studies have used protein microarrays as analytical tools to identify 
biomarkers using analytical protein microarrays. These allow for the detection of varying 
expression levels of proteins in a cell lysate as well as binding affinities and specificities 
of a sample. One newer technique that has emerged uses cell or tissue lysates as the 
arrayed substance (reverse-phase protein microarray). This powerful tool allows for the 
determination of altered protein modifications from two different samples, allowing 
researchers to identify potential biomarkers in diseased tissue. Perhaps the most well-
used microarray type is the functional protein microarray, or “target protein microarray.” 
The ability to performed hundreds or thousands of individual reactions in parallel 
becomes an unbiased and powerful tool that scientists can use to draw conclusions at a 
global or systematic level. 
As science and technology continues to advance, new approaches to old 
paradigms are often challenged. My thesis projects involve utilizing protein microarrays 
and bioinformatics to change how we view phosphorylation events and the cross-talk 
between phosphorylation and glycosylation.  
The wealth of information in databases continues to grow as larger proteomic-
wide studies are carried out and deposited for all to use. This allows bioinformaticians to 
predict new interactions that were never possible before. One such interaction involves 
 iii 
scaffolding proteins, proteins that can interact with at least two other proteins in signaling 
pathways. Scaffolding proteins have been studied for years and have been found to play 
critical roles in cellular signal transduction. In this study, human protein-protein 
interaction (PPI) and kinase-substrate relationship (KSR) networks were used to predict 
scaffolding proteins involved in phosphorylation signal transduction. We predicted 212 
scaffolding proteins involving 612 non-redundant phosphorylation pathways. One third 
(359 of the 1,103 known KSRs) of the phosphorylation-mediated signaling pathways are 
known to be regulated by at least one scaffold protein.  
We examined that the predicted scaffolding proteins are enriched for protein 
domains known to interact with phosphorylation sites, and exhibit similar characteristics 
of other known scaffolding proteins. Intriguingly, the predicted scaffolding proteins tend 
to have large protein sizes, perhaps due to their ability to adapt to multiple interactions 
with other proteins. Furthermore, these proteins are more evolutionarily conserved, 
suggesting important roles in different biological processes across species. When 
comparing to other human proteins, scaffolding proteins also contain more known 
phosphorylation sites, indicating that the scaffolds themselves might be regulated by 
phosphorylation-mediated signal transduction.  
In order to test these predictions, microarrays were employed on the human 
proteome microarray, which contains over 17,000 full-length human proteins. CSNK2A1 
(with predicted scaffolds PIN1 and ATF2) and MAPK9 (with predicted scaffold ATF2) 
were used to treat these microarrays in the presence of 
33
P-γ-ATP. After careful 
alignment and scoring, the predicted scaffolding proteins PIN1 and ATF2 were shown to 
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mediate 28 distinct phosphorylation events. Through this initial study, we have shown 
that our initial predictions appear to hold merit. 
Mutations and dysregulation of kinases play causal roles in human disease, 
development, cell signaling, and metabolism. Understanding the function of kinases 
continues to be of interest for biomarker discovery as well as for the development of 
agonists and antagonists for use in disease therapy. O-linked β-N-acetylglucosamine (O-
GlcNAc) is a post-translational modification known to regulate a variety of protein 
functions, including localization, enzyme activity, and protein stability. Like 
phosphorylation, O-GlcNAcylation modifies serine and threonine residues on nuclear and 
cytoplasmic proteins, and is a ubiquitous and reversible process that regulates cellular 
signaling. Recent evidence indicates that site-specific crosstalk between O-
GlcNAcylation and phosphorylation as well as the O-GlcNAcylation of kinases plays an 
important role in regulating cell signaling. Therefore, it is very important to study the O-
GlcNAcylation of the kinome. Previous studies utilizing a functional kinase array were 
able to identify 42 kinases as substrates of O-Glycosyltransferase (OGT) using an in vitro 
OGT assay with [H
3
] radiolabeling. While some promising results were obtained, the 
limitations of [H
3
] labeling demand a more sensitive approach if one is to examine a 
larger library of proteins.  
Herein, using multiple in vitro OGT labeling assays and immunofluorescent 
detection techniques, we were able to obtain a high confidence hit list based on shared 
hits from three different detection methods. A kinome array was fabricated, which 
contains 350 unique full-length human kinases representing approximately 70% of the 
human kinome. After in vitro labeling by OGT, arrays were treated either with one of two 
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Cy5-labeled antibodies that recognize O-GlcNAcylated residues (RL2 and CTD110.6) or 
with β-1,4-galactosyltransferase (GalT1 (Y289L)), which transfers azido-modified 
galactose (GalNAz) from UDP-GalNAz to O-GlcNAc residues of modified proteins. A 
simple click chemistry reaction followed with incubation of Alexa Fluor® 647 DIBO 
alkyne to fluorescently label the hits. Data analysis revealed that these hits were very 
reproducible and a total of 104 kinases were shared between all three methods.  
Many hits were subsequently validated both in vitro and in vivo, further validating 
our methods. Among the hits, O-GlcNAcylated sites were identified via mass 
spectrometry for BRSK2 and PAK4, with mutagenesis studies on the latter validating the 
identification. Through this simple, yet sensitive strategy, we have shown with high 
confidence that at least 20% of the human kinome (and 31% of those kinases tested) is 
glycosylated and the dataset created will likely spawn many further validation studies in 
the future. 
In conclusion, we show the utility of both bioinformatics and microarrays to 
predict novel functions of proteins and to probe an entire family of proteins for post-
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Chapter 1: Protein Microarrays and Their Applications 
 
1.1 History of Protein Microarrays 
 
 In 1983, Tse-Wan Chang spotted a variety of antibodies onto a glass slide in a 
matrix formation in order to study “the potential of simultaneous multiple determinations 
of specific cell surface antigens in one reaction incubation (Chang, 1983).”  This study 
represents one of the first concepts of what we today refer to as a microarray.  This notion 
blossomed into ambient analyte immunoassays, introduced by Roger Ekins in 1989, in 
which two fluorescently labeled antibodies were used to detect the occupation of a 
“sensing” antibody spotted on a slide (Ekins, 1989).  Over the next ten years, the concept 
was transformed into DNA microarrays, which allow for the detection of mRNA 
expression levels of thousands of genes in parallel.  
However, it was found that mRNA levels do not always correlate with protein 
expression, so the technology expanded further through the creation of protein 
microarrays in order to overcome some of these limitations (Gygi et al., 1999; Zhu et al., 
2001; Kopf et al., 2007).  Although DNA microarrays provide a useful platform for 
biological studies, they cannot emulate the function of what many consider the 
workhorses of the cell – proteins.  
 Protein array technology was developed in the early stages by organizing bacterial 
strains of a cDNA library on a nylon membrane, lysing the bacteria, and immobilizing the 
total protein complement (Bussow et al. 1998).  Although the technology was promising, 
it suffered from four critical issues.  First, the human proteins were expressed in bacteria, 
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so they lacked the critical post-translational modifications found in eukaryotes; second, 
the bacterial lysis was performed in denaturing conditions, resulting in misfolded 
proteins; third, the proteins of interest were not separated from the thousands of bacterial 
proteins from the cell lysate; and finally, the overall density of the array was very low.  
The purity and density problems were quickly resolved by a variety of groups, who used 
either purified proteins (MacBeath et al., 2000; Zhu et al., 2000; Ge, 2000) or antibodies 
(Schweitzer et al., 2000) for their arrays.   
 In 2001, the first study using these high-density arrays was presented by the 
Snyder group at Yale (Zhu et al., 2001).  This “proteome” microarray began by 
expressing approximately 5,800 full-length yeast open reading frames (ORFs) 
individually in yeast, where they were purified as N-terminal GST-fusion proteins.  The 
proteins were then spotted on a glass slide in duplicate robotically to form the first high-
density “proteome” microarray, as it contained more than 75% of the known yeast 
proteome.  Since this time, many more proteome microarrays have been created from 
viruses, bacteria, plants, and humans (Zhu et al., 2006; Chen et al., 2008; Popescu et al., 
2007; Jeong et al., 2012).   
 
1.2 Types of Protein Microarrays 
 
 There are three accepted types of protein microarrays that have been created, all 
with different functions and benefits: analytical, functional, and reverse-phase.  In the 
next section we will define and compare the differences between these three classes of 
microarrays (Figure 1.1).  
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Figure 1.1.  The three types of protein microarrays. (A) Analytical protein microarrays generally are fabricated with antibodies on a 
glass surface.  Analyte can be labeled directly, identified via a tag, or identified with a separate labeled antibody.  (B) Functional 
protein microarrays constitute the largest diversity in their applications.  Simple binding assays can be performed and are usually 
tethered to a fluorescent protein, but can also utilize tight non-covalent interactions (i.e. biotin-streptavidin).  Post-translational 
modification studies utilize an enzyme of interest with a labeled co-factor for detections of de novo modifications.  (C) Reverse-phase 
protein microarrays consist of probing complex mixtures of proteins, such as a cell lysate, with very specific antibodies.  Multicolor 


































Analytical Protein Microarrays 
 
 Analytical microarrays focus on protein detection from a complex mixture of 
proteins (Figure 1.1 A).  The canonical example of this type of array is the antibody 
array, which uses an assortment of spotted antibodies to capture proteins from a cell 
lysate.  This is most commonly performed using a process called direct protein labeling.  
In this technique, protein samples are labeled with a fluorophore before binding to the 
array.  Protein labeling can be useful for high-abundance proteins, but suffers from low 
sensitivity and specificity in target labeling.  A sandwich approach was developed to 
increase the sensitivity by using two separate antibodies to detect the target protein.  The 
“capture” antibody is immobilized onto the solid phase, where it binds the protein of 
interest.  The second “reporter” antibody contains the fluorescent label and binds to the 
target protein, leading to much greater sensitivity and specificity, even down to 
femtomolar concentrations (Poetz et al., 2005).  Although antibodies are the primary 
means of protein capture for analytical microarrays, they do have some sizeable 
disadvantages.  For starters, the specificity of the antibodies can vary considerably and 
can cross-react with many other proteins, resulting in a large amount of false positives.  
Another hurdle is due to the difficulty in producing large quantities of antibodies in a 
high-throughput fashion.  The advent of recombinant antibodies holds a promising means 
of overcoming this, but complex production issues need to be addressed before this 




Functional Protein Microarrays 
  
The second class of protein microarrays is the functional protein microarray 
(Figure 1.1 B).  These arrays consist of individually purified proteins immobilized to a 
glass slide and are used in a variety of biochemical reactions or assays.  Unlike the 
analytical arrays, which focus on detections from a complex protein mixture, functional 
microarrays generally consist of treating the array with a single purified protein in order 
to study its interaction with the proteins on the chip.  These interactions can vary from 
binding activities (protein-protein, protein-DNA, protein-lipid, protein-drug) to enzyme-
substrate relationships, which are analyzed from a biochemical assay performed on the 
array (phosphorylation, ubiquitylation, acetylation, glycosylation, SUMOylation, 
nitrosylation) (Poetz et al., 2005; Chen et al., 2006).  One large advantage is derived from 
the sheer amount of diverse experiments that can be applied to the array, but caution must 
be applied when labeling hits as true in vivo interactions.  Although many assays involve 
the use of purified proteins, the interactions may not reflect what actually occurs in a 
living system.  Conversely, some true interactions may not be seen due to the absence of 
co-factors in the reaction mix.  Because of this, any interactions identified on a functional 
array must be further characterized before conclusions can be drawn.   
 
Reverse-Phase Protein Microarrays 
 
 Reverse-phase protein microarrays are unique in that they employ the opposite 
format to the classical microarray (Figure 1.1 C).  Tissues, cell lysates, or cell 
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fractionations from different states are immobilized to a glass slide, where they can be 
treated with a variety of probes to identify a protein of interest.  Cloud Paweletz was one 
of the first to use this method in his analysis of histological changes in prostate cancer 
patients (Paweletz, et al., 2001).  In this study, lysates from three different stages of 
prostate cancer from many patients were immobilized: normal prostate epithelium, 
prostate intraepithelial neoplasia, and invasive prostate cancer.  They were then able to 
detect and quantify the phosphorylation states of a variety of proteins, including Akt and 
ERK, throughout the progression of the disease.  This technique was sensitive, precise, 
and linear enough to detect even the smallest changes between samples, and they were 
able to show a positive correlation between phosphorylation state and prostate cancer 
progression.  This method shows great promise going forward, but like the analytical 



















RayBiotech Analytical Antibodies against 71 
human kinases 
 PlasmaScan 380 
Antibody Microarray 
Arrayit Analytical Antibodies for detection of 
human plasma 




Analytical Antibodies against 77 
human cytokines 












BioCat Analytical 185 phospho-protein 
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multiple pathways 
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ProtoArray Invitrogen Functional 9,000 human proteins 
 Kinex Kinexus 
Bioinformatics 
Functional 200 human kinases 
Pathogen Arrays Arrayit Pathogen 
Antigen Microarray 








Variety of human cancer 
cell lysates 
Table 1.  Commercially Available Protein Microarrays 
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 As mentioned before, one of the largest hurdles in microarray technology has 
been the high-throughput purification of protein samples.  Unlike DNA, which can be 
synthesized in situ with the same properties as in the cell, proteins cannot be synthesized 
in vitro at high efficiency because of their complex chemistry.  Therefore, new 
technologies had to be developed to accommodate the need for very pure and functional 
proteins. 
 Recombinant antibodies have provided a useful alternative to the traditional 
hybridoma-based technology used for high-quality antibody purification.  Phage display 
was one of the earliest techniques used for recombinant antibody production.  Using 
antibody-fragment encoding genes (VH and VL) and bacteriophage capsid gene fusion, 
large sets of human antibody libraries are stored in prokaryotic systems, where they can 
be easily expressed by phage infection (Carmen et al., 2002).  After expression, they are 
displayed in the phage capsid and purified using column chromatography.  These 
antibodies also have the advantage of not containing the Fc domain that intact IgG 
antibodies contain, therefore eliminating non-specific binding to the Fc receptor 
(Knappik et al., 2009).  More recently, other approaches have been developed as well for 
the production of recombinant antibodies, including the eukaryotic expression system of 
yeast display (Chao et al., 2006).  Using yeast is beneficial in maintaining some of the 
post-translational modifications that are absent when using bacteria.   
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 The development of functional microarrays faces a large hurdle as well because of 
the large quantities of highly purified proteins that are needed.  Not only do the proteins 
need to be free of contaminants, they also require conditions that facilitate proper folding, 
native post translational modifications, and require optimal physical conditions during the 
purification.  To this end, large-scale purifications have been developed using both yeast 
(Saccharomyces cerevisiae) and bacteria (Escherichia coli) expressions systems (Zhu et 
al., 2001; Chen et al., 2008; Jeong et al., 2012; Zhu et al., 2007).  Several advantages 
exist in producing human proteins in yeast rather than in bacteria: (1) higher solubility; 
(2) higher yields of large proteins (e.g. > 50 kD); (3) better preserved conformation; (4) 
less immunogenicity; and (5) they contain many, but not all, of the native post-
translational modifications that a prokaryotic system cannot provide.  While both can 
utilize batch purification in a 96-well format to purify thousands of proteins at a time, 
many labs cannot undergo such a large endeavor.   
In 2004, Ramachandran et al. developed a novel technique called the nucleic acid 
programmable protein array (NAPPA).  Plasmid DNA is biotinylated and immobilized on 
a streptavidin surface adjacent to an affinity-tag antibody (e.g. GST).  The GST-tagged 
protein is then synthesized via in situ transcription/translation and immediately binds to 
the antibody.  This allows for the generation of over ten thousand proteins on one slide 
without the tedious cloning and purification steps, and slides can be stored long-term 
(Ramachandran et al., 2004).  However, the array is not “pure” as the proteins are co-
localized with the DNA and can provide some unwanted interactions.  Alternatively, the 
PISA method (protein in situ array) bypasses the immobilization of DNA on the array by 
using free DNA in a reaction mixture on an affinity-tagged surface (He et al., 2001).  
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Angenendt et al. created an array containing over 13,000 spots using a robotic system to 
accurately mix sub-nanoliter reactions containing the necessary transcription/translation 
machinery (Angenendt et al., 2006).  After the protein is translated in the nanodrops, they 
bind to the surface of the slide and the DNA is washed away, leaving a “pure” array.  
While these cell-free methods of creating protein microarrays eliminate the need for 
large-scale cloning and purifications, they have not been widely utilized because of the 
low protein yield, the absence of post-translational modifications, and the difficulties in 




 Once the proteins have been purified, the solid support in which they are 
immobilized is another factor to be considered.  An optimal surface is one that allows for 
proteins to be tightly bound while still maintaining their three-dimensional conformation, 
yield high signal-to-noise ratios, and have a long shelf life.  Popular types include 
adsorption, diffusion, covalent immobilization, affinity capture, and metal.   
 In the early life of this technology, glass slides coated with polyvinylidene 
fluoride (PVDF), nitrocellulose, or polystyrene were used.  Through simple adsorption, 
proteins were easily arrayed (Stillman et al., 2000).  However, because these surfaces are 
relatively soft, they allowed protein spots to spread out, decreasing the overall density of 
each spot.  It was also found that many applications generate high background for a low 
signal-to-noise ratio.  Another approach uses an agarose/polyacrylamide gel to 
immobilize proteins in their native conformation and the hydrophilic matrix prevents the 
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lateral movement found in the PVDF-coated membranes.  Because of the restriction in 
movement of the proteins, the size of each spot is decreased, resulting in a greater 
number of total proteins allowed on the array (Charles et al., 2004).  Aldehyde- or epoxy-
derivatized glass surfaces are a third popular surface that forms covalent bonds with the 
printed proteins.  These provide strong binding interactions and relatively low 
backgrounds, but protein orientation is randomized (MacBeath et al., 2000).  If protein 
orientation is critical, surfaces coated with streptavidin, glutathione, or nickel allow for 
biotin-, GST-, or His-tagged proteins, respectively, to bind tightly in a non-covalent 
manner.  By having all the proteins in the same conformation, a large increase in signal-
to-noise ratio can be achieved (Zhu et al., 2001).  The final surface that is currently being 
used involves the adsorption of proteins onto a surface coated with gold, silver, or steel.  
In the case of the gold coated arrays, porous gold is deposited onto a bare gold surface 
and the substrate is patterned with methyl and carboxy-terminated SAMs (self-assembled 
monolayers).  This creates well-defined hydrophilic spots (carboxy-terminated) where the 
substrates are covalently attached, and a superhydrophobic background is formed 
(methyl-terminated) that minimizes protein adsorption from biological solutions.  
Proteins arrayed in this manner facilitate MALDI-TOF detection of protein arrays 
(Evans-Nguyen et al., 2008).  This type of array is also compatible with surface plasmon 
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 Careful placement of purified samples is crucial when fabricating microarrays.  
Spots must be homogenous and dense, yet spatially discrete, therefore robotic systems are 
often used to “print” a surface with samples.  There are two methods of spot formation, 
contact printing and non-contact printing.  Each of these methods can also be done in 
serial (one sample at a time) or in parallel (multiple samples at a time).  In this next 
section we will discuss the wide variations in these methods as well as their respective 
advantages and disadvantages (Barbulovic-Nad et al., 2006). 
 Contact printing involves direct contact between a printing device and the 
substrate.  The printing device first comes in contact with a sample, which adheres to the 
apparatus via surface tension.  It then physically contacts the solid surface, where the 
sample is attached covalently or non-covalently, depending on which surface is used.  
These technologies use a variety of tools, including solid pins, split pins, microstamps, 
and nano-tips.  Initial microarrays used a single pin for fabrication, but that was quickly 
evolved into an array of pins to increase throughput.  Pin printing is considered serial 
printing, while microstamps deposit large amounts of sample in a parallel fashion.  Nano-
tip printing is based on Atomic Force Microscopy (AFM) and can generate arrays with 
submicron spots.   
 Pin printing is one of the most common forms of microarray fabrication.  There 
are a variety of pins that can be used, each with its own characteristics.  Solid pins are the 
most simple and were the first to be used.  They consist of a solid piece of metal that is 
dipped into the sample solution to “load” the tip.  Capillary force action allows for the 
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sample to be loaded as a small bead on the tip of the pin, and it is deposited on a solid 
surface once the pin comes in contact with it.  The pins vary in shape, from convex to flat 
to concave.  One loaded sample can print only a few spots, which is why these pins are 
generally only used for low-density arrays.  They do offer a few advantages, however.  If 
sample solutions are very viscous, they can clog the split-pin types, which is not an issue 
for solid pins.  Cleaning of these pins is also much easier, so arrays are typically very 
reliable between batches.   
The most common type of pin that is used today is the split pin.  These pins 
contain small (60-100 μm) slits in the center of the pin that allow a greater volume of 
sample to be loaded in each dip with capillary action, greatly increasing throughput.  
However, because the same pins are often used to handle multiple samples, they have to 
be carefully washed between samples.  This typically includes a sonication bath step 
between samples to assure that all sample liquid is removed.  Some disadvantages need to 
be considered, however.  Although made of metal (typically solid steel, tungsten, or 
titanium), the very fine tips can still be subject to deformation from the tapping force and 
lead to uneven spotting.  Dust and contaminants as well as highly viscous solutions can 
lead to clogging as well.  This can be resolved by using a wider slit, but spot size 
reproducibility is affected.  Choosing the right pinhead will depend on the sample, so 
careful consideration must be applied to achieve optimal conditions.   
The actual printing system involves a pin head (holding anywhere from 16 to 96 
pins) attached to a translation system, a sample plate, and a flat plane with the carefully 
positioned solid surface substrates (Figure 1.2).  The pins are free to move vertically 
while in the pin head, so there is flexibility when they come in contact with the solid 
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surface.  The translation machinery moves the pin head to the source plate, where the 
pins are lowered to collect the sample through capillary action.  The sample is held by 
surface tension either on the tip (solid pins) or within the capillary (split pins).  The pin 
head is then positioned over the solid surface and gently, but reproducibly, tapped, 
dispensing the sample onto the solid surface where it is immobilized.  Spot sizes are 
defined by many factors, including sample viscosity, pin velocity, substrate surface 
properties, precision of the robotic controls, humidity, and temperature.  Although pin 
printing represents the most popular form of microarray fabrication, it can be time 
consuming.  For example, a single 384-well source plate printing can take up to 6.4 
hours, so other spotting methods were developed to overcome this limitation.   
 
Figure 1.2.  General diagram of a contact printing apparatus.  A pin head, which typically holds between 16 and 96 pins, is attached to 
a translation system, which can accurately and reproducibly move in 3-D space.  The pins are first dipped into a sample plate, where 
the sample adheres to the pins with capillary action.  The pins are then moved above the arranged substrates and spotted by physically 
tapping the surface.  As a serial printing technique, this is generally time-consuming, as a single 384-well source plate can take over 6 
hours to fabricate.  
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Microstamping is a serial contact printing technique that is both simple and cheap 
enough to be performed in any laboratory, while allowing for the high-throughput 
fabrication of protein microarrays.  The basic protocol involves a protein sample being 
adsorbed onto a patterned surface and then transferred to a substrate using physical 
contact.  Obtaining good contact is critical in the sample spotting, so elastomeric 
materials, such as poly(dimethylsiloxane) (PDMS) are generally used because they 
conform to solid surfaces under an applied load.  These elastomeric stamps are produced 
using a micromolding technique that requires a single photolithography step.  A master 
mold is created by photolithography, followed by casting of an uncured elastomer onto 
the mold.  After curing, the stamp is removed from the mold, where it can be used to 
adsorb to samples.  Through this process, many disposable stamps can be easily 
fabricated, eliminating the need for the washing between samples that is required for pin 
printing.  The major disadvantages of the stamping method involve the amount of sample 
that can be transferred.  The sample volume transferred from stamp to substrate is not 
well controlled and depends greatly on the surface and sample properties.  Moreover, 
initial sample volumes are much larger than in pin printing because only a small fraction 
adsorbs to the stamp and is deposited on the substrate, which can be a serious limitation 
when dealing with precious samples (such as patient tissues).  Spots are also much larger 
than what can be produced using pins (300 μm vs. 60 μm), which leads to decreased spot 
density.  Likewise, the washing of microstamps for reuse is more difficult and tedious 
than for pins due to the non-specific adsorption that can occur.   
Inking is the first step performed in microstamping and begins by treating the 
hydrophobic PDMS stamp with a hydrophilic film to insure sample adherence.  Similar to 
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a standard ink and rubber stamp, the microstamp is then simply inked by dipping into a 
sample well, where hydrophilic interactions mediate adsorption onto the stamp.  In order 
to obtain uniformity in the amount of sample that is adsorbed to the stamps sites, some 
new techniques have been developed.  Injecting devices called piezoneedles have been 
used to deliver equal amounts of DNA solution to stamp sites.  This technique exhibits 
good control of spot size and is able to produce multiple arrays from a single inking step.  
Another technique involves loading the sample solution into wells on the back of a 
stamp.  The solutions flow through microchannels down to the stamp tips through surface 
tension, and are deposited onto the substrate when careful pressure is applied. 
Two types of stamping are used, direct and indirect.  Direct stamping involves the 
stamp directly interacting with a biological sample before being brought into physical 
contact with the substrate, typically for a few seconds to ensure good conformation.  The 
stamp is then removed, leaving the sample behind.  Using the necessary speed, contact 
angle, surface roughness and spacing between stamp sites is needed to achieve uniform 
shape and volume in spots.  One type of direct stamping technique involves a 
microfluidic design, which contains both inlet and outlet ports for which the biological 
sample can be channeled.  A stamp is pressed onto the substrate and the sample solution 
flows through the channel and prints a spot onto the substrate.  This process can be used 
to print incredibly concentrated samples because the number of desired molecules can be 
immobilized to the substrate without washing away unwanted materials.   
In indirect stamping, the stamp is inked with chemical groups or self-assembled 
monolayers (SAMs) rather than with biological samples.  Typically SAMs are patterned 
on a gold substrate with alkanethiols, in which a head group adsorbs onto the gold 
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surface, followed by a long polymer carbon chain, and ending with a reactive tail group.  
The stamp first prints an array using a particular alkanethiol (AT1) onto a gold substrate 
using traditional contact methods.  Next, the remaining un-modified gold surface is 
coated with a secondary alkanethiol (AT2).  Samples are designed so that they selectively 
react only with the AT1 head group and an array is formed.  This type of printing is not 
suitable if more than one sample is to be arrayed, as non-specific adsorption and cross-
reactivity can easily occur.   
Nano-tip printing is the third method of contact printing techniques that is 
currently employed for microarray production.  These technologies are able to print spots 
at the sub-micron level through the use of atomic force microscopy (AFM).  AFM nano-
tips are used in two ways: (1) adding a sample or sample binding molecules to a substrate 
(dip-pen lithography); or (2) removing SAM molecules from a coated surface (ATM 
grafting).   
Dip-pen lithography uses a similar schematic to indirect sampling, but can do so 
at a much smaller, sub-micron level (compared to spots 300 μm in diameter obtained 
through microstamp printing).  A sample that binds proteins is transferred to the substrate 
with the nano-tip in a patterned array.  The remaining areas are blocked with molecules 
resistant to protein adsorption, as before.  The arrays are finally treated with a biological 
sample, which only binds to the compatible surface.  This has been shown to create 
monolayers only 30 nm wide.   
AFM grafting, conversely, uses the nano-tip to remove one SAM layer (consisting 
of molecules resistant to protein adsorption) at selected sites, followed by treatment with 
reactive SAM molecules to fill in the gaps.  This is useful when nano-patterns need to be 
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modified in situ, eliminating the need to repeat the entire process.  The utility of this 
fabrication method is more limited than the other two for a few reasons.  One, it is a serial 
technique, so it is much slower than microstamping.  The slow speed reduces fabrication 
efficiency as well, as sample volumes must be very small because they tend to dry up 
during the printing process.  Also, as the individual spots approach protein-size levels, 
non-specific binding can become a large issue.  Finally, this approach, like indirect 
stamping, can generally only accommodate very few biological samples at a time, 
compared to the thousands of unique proteins that can be printed using either direct 
stamping or pin printing techniques.  However, the greatest advantage arises from the fact 
that both the printing and detection of the microarrays can be performed on the same 
instrument, as AFM has been shown to be able to detect protein-biological sample 
interactions (as described later in label independent detection methods).     
In contrast to contact printing, which all involved direct physical interaction 
between printer and substrate, non-contact printing approaches obviously do not.  These 
techniques range from photochemistry-based methods to fluid droplet dispensing 
methods, but all share the same advantages: reduced contamination and higher 
throughput.  By separating the printer from the substrate at all times, cross-contamination 
between samples is dramatically reduced.  Additionally, the need to clean the printing 
devices between samples is also eliminated.  Moreover, non-contact printing techniques 
offer the potential to increase throughput over other techniques.  Many can also deposit 
solutions in parallel, allowing entire arrays to be produced simultaneously.   
Photochemistry microarray printing involves chemical treatment of the substrate, 
followed by UV light exposure through photomasks.  Two types of photochemistry 
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techniques are used, photolithography and direct photochemical patterning.  In the 
photolithography approach, a photoresist layer is coated onto a substrate surface, 
followed by UV light exposure through a patterned photomask (Figure 1.3 A).  This 
forms micrometer-sized open regions where adhesion-promoting molecules can then 
bind.  The remaining photoresist layer is removed and the substrate is incubated with 
adhesion-resisting molecules.  
 
Figure 1.3.  Photochemical microarray printing as a non-contact printing approach.  (A) Photolithography printing first involves 
coating a glass surface with a photoresist coating.  Illuminating the surface with UV light through a patterned photomask creates a 
patterned photoresist.  The ablated spots are then treated with protein-binding molecules.  After the remaining photoresist is removed, 
the remaining glass surface is coated in protein resisting molecules.  Finally the protein mixture is added, where it can adhere to the 
array in a patterned format.  (B) A similar approach, direct photochemical patterning, uses glass slides coated with photochemical 
molecules first in the presence of biological samples.  UV light is again shone through a patterned photoresist, specifically activating 
these molecules, and allowing the proteins to bind.  Both of these methods are limited in the diversity of samples that can be spotted, 
but benefit from the speed in which they can be fabricated.  
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Direct photochemical patterning is similar to photo-lithographic techniques, but it 
does not require a photoresist layer (Figure 1.3 B).  Substrates are coated with 
photochemical molecules and activated by UV light through photomasks, where they can 
subsequently bind to biological molecules.  These techniques are high throughput, but 
again, are limited in the variety of samples that can be patterned at once.   
The other type of non-contact printing technique involves dispensing droplets of 
protein sample onto a substrate.  The three most commonly used approaches are inkjet 
printing, electrospray deposition (ESD), and laser writing.   
 In an effort to reduce the cost of microarray printing machinery, attempts have 
been made to find cheaper alternatives in commonly available products.  Oftentimes, 
commercially available printers are modified to dispense biological materials instead of 
ink.  There are two commonly used inkjet printing techniques, thermal and piezoelectric.  
Thermal printers utilize resistive heaters (with temperatures reaching upwards of 200° C) 
for sample droplet dispensing, while piezoelectric printers use piezoelectric actuators to 
dispense droplets onto the substrate surface.  Although an attractive technique, there are 
several disadvantages.  For starters, commercially available printers are not designed to 
print on glass slides, so they are limited to flexible membranes such as cellulose, nylon, 
and nitrocellulose.  These surfaces can lead to smearing, and therefore contamination 
between samples.  Secondly, the nozzles used in inkjet printing tend to produce 
“satellite” spots surrounding the spot of interest, reducing printer resolution.  Cleaning of 
the nozzles is also difficult, especially in piezoelectric printers.  Finally, samples can 
experience high shear rates and high temperatures, regardless of the method used, which 
can result in the denaturing of biological samples.  Some studies have shown an ability to 
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overcome some of these problems, namely the cleansing issue, by using deposition heads 
with large numbers of top loaded reservoirs (Gutmann et al., 2004).  Many droplets from 
different samples can therefore be printed simultaneously.   
 Similar to inkjet printing, electrospray deposition (ESD) is a technique that has 
been modified from an existing application to be used with biological samples.  ESD has 
been typically used to deposit thin films of polymers, semiconductive ceramics, and 
radioactive sources, but many have begun using it to deposit biological samples to a 
substrate for microarray fabrication.  The general technique uses a dielectric mask placed 
between the capillaries containing biological samples and the substrate.  An electrostatic 
field in produced between the capillary and the substrate, driving the solution out of the 
capillary nozzle.  As the inverse charge is applied below the surface of the substrate, the 
biological samples are attracted to the surface, but can only pass through the holes of the 
dielectric mask, where they are deposited.  Each capillary is filled with a different 
substrate, and sequentially activated after movements of the mask to different spots on 
the array.  This allows for fast and parallel fabrication of microarrays, as well as the 
production of very small spots (2-6 μm).  However, although spot size can be small, the 
distance between spots (called “pitch”) is relatively large, on the order of 1 mm.  This 
limits the overall number of spots that can be arrayed onto a single substrate slide.  
Another limitation arises from differences in droplet distribution from the spraying 
technique.  Generally, only those spots directly below the capillary produce high-density 
spots, but surrounding spots are generally quite irregular in regards to density.  However, 
because the pitch is so large, cross-contamination is generally not an issue.  High shear 
rates can be damaging as well, as the solution becomes charged due to the electrostatic 
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field.  This field can cause deformations in proteins, as well as alterations in solution pH, 
so it is important to take into consideration when selecting samples to use with this 
method.   
 The final method of non-contact printing uses laser ablation to produce protein 
microarrays, either directly or indirectly.  In direct writing, a sample is mixed with 
glycerol and buffer and coated on a quartz disc.  As a pulsed laser is scanned across the 
disc and local evaporation occurs, producing microscopic droplets that fall to the 
substrate surface.  The droplets produced are smaller than one can get using traditional 
pin methods (50 μm) and does so with very little sample.  Using this technique, over 
16,000 arrays can be produced with only 500 nL of starting material.  Indirect writing is a 
process that is similar to many of the other “lift-off” techniques mentioned before.  A 
photoresist layer is placed on top of a substrate and is selectively removed with a 
photomask and laser, leaving patterned pockets with which to apply biological samples.   
 While all these non-contact printing methods hold great promise for the 
production of sub-micron spots, all require high shear, high temperatures, or both.  
Therefore careful consideration must be had when choosing to use these approaches. 
 In summary, there have been many attempts by various labs to create a fabrication 
system that optimizes uniformity, minimizes sample volume, and does so without 
contamination of the biological samples.  Pin printing remains the most popular player in 
this process, as it overall provides the most reproducible arrays with little maintenance, 
albeit with the highest cost.  Many of the ablation techniques can produce very small 
spots, but are severely limited in the number of unique samples that can be spotted on one 
array.  Non-contact techniques eliminate many of the contamination concerns present in 
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pin and stamp printing, but at the cost of high temperatures and shear forces.  As these 
technologies inevitably advance, these shortcomings have promise to be overcome.   
 
1.4 Detection Methods 
 
The detection methods used for protein microarrays are another important design 
parameter.  There are two classes of detection: Label dependent and label free.   
 
Figure 1.4.  Detection methods used in protein microarray experiments.  (A) Label dependent detection can alter protein 
activity, but provide great sensitivity.  Fluorescent dyes are among the most commonly used, and can utilize multiple colors for 
detection of multiple interactions (i.e., acetylation and protein levels, concurrently).  Chemiluminescent techniques can also be 
used, such as horseradish peroxidase (HRP).  RCA approaches are useful with low abundance proteins, as they can greatly 
amplify the signal.  Radioisotopes are useful for de novo assays and are preferred when specific antibodies are not available.  
(B) Label free methods eliminate the possibility of altering protein activity, but at the cost of expensive equipment and lower 
throughput.  Mass spectrometry approaches can be used with complex mixtures.  Atomic Force Microscopy (AFM) can detect 
ligand binding by sensing a change in height as a cantilever moves across the array.  Surface Plasmon Resonance (SPR) is used 
to detect binding in real-time by observing changes in incidence light from the resonance of the surface plasmon when a ligand 
binds to and dissociates from its target.  Oblique-Incidence Reflectivity Difference (O-IRD) detects changes in reflectivity 
between p- and s-polarizations, and can likewise be used to detect changes in biological samples from ligand binding in real-




















































 Several types of label dependent detection methods have been developed and 
optimized (Figure 1.4 A).  The first is the use of fluorescent dyes with narrow excitation 
and emission spectra, such as Cy3 or Cy5.  These are most commonly used for their 
convenience and wide detection range.  Furthermore, they can also provide a multi-color 
system for multiplex assay design (Fu, 2007).  Enzymatic methods can also be used to 
enhance signal amplification.  The most common is horseradish peroxidase, but others 
include a modified rolling circle amplification (RCA) label that uses DNA primers 
attached to antibodies to create binding partners for fluorescent, complementary 
oligonucleotide probes.  This is especially useful for the detection of low abundance 
proteins, where the sensitivity of chemiluminescence and traditional fluorescence is too 
low (Schweitzer et al., 2002).  Other assays that involve enzymatic reactions on the 






C) for de novo detection.  
While this can provide superior signal-to-noise ratios, and can be the only reliable 
detection method for modifications without high-affinity antibodies, many oppose this 
method due to safety concerns (Chen et al., 2006).   
 
Label Free Detection 
 
 Although useful, labeling processes can alter protein activity, so many label free 
methods have been developed (Figure 1.4 B).  Mass spectrometry has been used for the 
detection of ligand binding, using MALDI-MS, SELDI-TOF-MS, and MALDI-TOF-MS 
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approaches (Gavin et al., 2005; Diamond et al., 2003; Evans-Nguyen et al., 2008).  This 
approach can be done quickly and simply and with very little sample, and can also be 
used to directly detect analytes bound from complex samples such as urine, serum, 
plasma, and cell lysates (Zhang, 2012).  Atomic force microscopy (AFM) is another 
approach that can identify analytes bound to an array by detecting a change in height of 
the samples on the array, which leads to measurable binding interactions (Yan et al., 
2003).  Another advantage of label-free methods arises from the ability to detect real-time 
dynamics of protein interactions.  Surface plasmon resonance (SPR) has been used to 
analyze bimolecular interactions in real-time and has been adapted for the protein 
microarray (Wegner et al., 2003; Unfricht et al., 2005).  Incident light can resonate with 
plasma on a metal surface in total internal reflection, causing resonance signals to change 
when ligands bind to (and dissociate from) proteins on the array surface.  In this way, 
binding events can be monitored in real-time and kinetic parameters can be calculated.  
As an extension of traditional SPR techniques, SPR imaging (SPRi) combines the 
sensitivity of SPR with the spatial capabilities of imaging.  A CCD camera is used to 
capture the light reflected from the entire surface and can be quantified by subtracting the 
background signal from the image taken before the experiment begins.  As samples flow 
over the surface of the array, multiple images are acquired, and reflectivity changes can 
be quantified in real-time with a visual output as well (Kodoyianni, 2011).  Similarly, the 
oblique-incidence reflectivity difference (O-IRD) approach allows for the very sensitive 
detection in the changes in reflectivity between the p- and s-polarizations.  It is also used 
for acquiring kinetic parameters by detecting the tiny changes in the physical properties 
of a biological sample, such as thickness and density (Landry et al., 2008).  
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1.5 Basic Research Applications 
 
 Among the growing fields of scientific research that utilizes the protein 
microarray, basic research has been at the forefront of this technology.  There is an 
incredible amount of diversity in the applications of this technology, which we will 
highlight in this section, and while these studies all involve the same general schematic, 
they all arrive at vastly different conclusions (Figure 1.5).  
 
Figure 1.5.  General schematic for microarray studies.  A typical microarray study involves three steps; (1) Completion and 
detection of assays; (2) Compiling data for bioinformaticians, where biologically relevant connections are first made; (3) 
validation and further observations.  In silico conclusions can be drawn through statistical algorithms, but all require further 
validation.  Many motifs types are commonly predicted from the commonalities between hits, such as binding motifs and PTM 
motifs.  Interactions can be combined with known data to formulate dense networks.  The final step generally requires some 
sort of in cellulo or in vivo validations.  One common weakness of all microarray studies arises from false-positives and false-
negatives that can arise from any in vivo system, so a combination of bioinformatics and cellular validation studies helps 
eliminate these biases.   
 
These studies include the detection of protein-binding interactions (protein-
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molecule, and protein-glycan), detection of prost-translational modifications 
(phosphorylation, ubiquitylation, acetylation, nitrosylation, sumoylation, and 
glycosylation), and profiling of monoclonal antibody specificity.  
 
Detection of Protein-Binding Interactions 
 
 One of the most basic fundamentals of cell signaling involves the physical 
interaction between biological molecules.  Identifying these interfaces is critical in 
developing our understanding of how our increasingly complex world works.  Many 
early studies have used two-hybrid screens to elucidate protein-protein and protein-DNA 
interactions (Vidal et al., 1996; Young, 1998; Joung et al., 2000).  This technique is a 
popular approach due to its low-tech nature and scalability, therefore is often used as a 
first step in identifying novel interactions.  However, there is criticism due to the many 
false positives and false negatives that can arise for a variety of issues.  As fusion 
proteins, some interactions may be inhibited due to the non-native nature of the protein.  
Hybridization also takes place in the nucleus, limiting the breadth of the studies to those 
proteins that localize to the nucleus.  Protein complex purification coupled with mass 
spectrometry analysis is another approach that has been established to identify novel 
protein-protein interactions (Krogan et al., 2006).  While this method has proved to have 
high fidelity, it is both time-consuming and not suitable for low abundance proteins.  
These issues, among others, contributed to the development of protein microarray 
technology for the study of protein-binding interactions.  These arrays can be screened in 
parallel quickly, reproducibly, and in high throughput.  One drawback lies in the inherent 
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in vitro nature of the assay itself, as interactions identified on the array may not occur in 
the context of a cell.  Therefore, hits must be further characterized in order to be truly 
validated.  Although not without some disadvantages, protein microarrays have become 





 MacBeath and Schreiber performed the seminal interaction study using this 
technology in 2000.  By utilizing the same robotic equipment used to print DNA 
microarrays, they were able to create high-density protein microarrays and identify 
protein-protein interactions, kinase substrates, and small molecule targets (MacBeath and 
Schreiber, 2000).  As a proof of principle, they first sought to prove that this technique 
allowed for the functional properties of the immobilized proteins to remain intact.  Three 
pairs of known interactors were used to test this hypothesis: Protein G and 
immunoglobulin G (IgG); p50 (of the NF-κB complex) and its inhibitor I-κBα; and the 
FKBP12-rapamycin binding (FRB) domain of FKBP-rapamycin-associated protein 
(FRAP) and the human immunophilin FKBP12 (12kD FK506-binding protein).  The first 
protein of each pair was immobilized on a glass surface followed by incubation with a 
fluorescently labeled pair.  Each pair utilized a different fluorophore and they were able 
to show that they each bound only to their respective interactors, even simultaneously.  
Another test involved printing 10,800 spots onto a glass slide, with 10,799 of them 
containing Protein G and one specifically printed with FRB.  Using a mixture of both 
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blue (IgG) and red (FKBP12) probes, they were able to show only one spot fluoresced 
red, only where the FRB was spotted.  This initial study signified that the immobilization 
of the proteins onto derivatized slides did not affect their binding properties.   
Shortly thereafter, Zhu et al. analyzed protein-protein interactions using test 
ligands labeled directly or indirectly with fluorescent dyes (Zhu et al., 2001).  Using the 
first “proteome” microarray mentioned before containing approximately 5,800 
recombinant yeast proteins (>85% of the yeast proteome), they were able to identify the 
binding partners of calmodulin (CaM).  After first incubating the microarray with 
biotinylated bovine CaM, the proteins were detected with Cy3-labeled streptavidin.  
Apart from identifying six known CaM targets, 33 new CaM binding partners were 
discovered.  Further bioinformatic analysis revealed a shared consensus motif between 14 
of the 39 binding partners: (I/L)QXXK(K/X)GB, where X is any residue and B is a basic 
residue.  Not only can targets be identified easily through this approach, motifs can also 
be deduced, further expanding the usefulness of these arrays.   
 In a related study, Popescu et al. developed a protein array consisting of 1,133 
Arabidopsis thaliana proteins to globally identify binding partners of CaM or 
calmodulin-like proteins (CML) (Popescu et al., 2007).  Instead of using biotinylated 
CaM, they used CaM amino-conjugated to Alex Fluor 647 to identify 173 different 
targets that bound to the three CaMs and four CMLs.  Like the yeast study, a large 
number of previously known CaM targets were identified, as well as a diverse group of 
transcription factors (TFs), receptor and intracellular protein kinases, RNA-binding 





 Apart from identifying CaM binding partners, Zhu and colleagues also identified 
the binding partners for 6 liposomes containing different phosphatidylinositides (PIs) on 
the yeast proteome array (Zhu et al., 2001).   The liposomes contained 1% N-(biotinoyl)-
1,2-dihexadecanoyl-sn-glycero-3-phospho-ethanolamine, triethylammonium salt (biotin-
DHPE) and were similarly detected using a streptavidin-labeled Cy3 fluorescent dye.  
The six liposomes were able to identify 150 different protein targets, including integral 
membrane proteins, anchored proteins, prenylated proteins, and lipid metabolism 
enzymes.  The binding interactions could also be characterized as “strong-binding” or 
“weak-binding” by comparing the fluorescent signal obtained by the liposomes to the 
fluorescent signal obtained from GST probing (this standard technique uses a Cy5 labeled 
antibody targeting the tag of the immobilized proteins on the array, yielding the relative 
protein concentration at each spot).  Through this analysis, they were able to correlate 
strong binders with membrane-associated proteins and that strong phosphoinositide-
binding proteins preferentially bound a specific PI.  Not only could binding interactions 
be identified, but conclusions can be drawn concerning the binding affinities of the 
various PIs.  This technique of comparing the binding/modification levels to the protein 
levels is one that is utilized often, and is another reason why protein microarrays are one 
of the more versatile platforms available.    
 More recently, Lu et al developed another fluorescent liposomal assay to identify 
binding partners for phosphatidylinositol 3,5-bisphosphate (PI(3,5)P22) using the same 
yeast proteome array used by Zhu (Lu et al., 2012).  A special non-quenched fluorescent 
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(NQF) liposome was developed that eliminates the need to lyse the liposomes in order to 
see fluorescent signal.  Using these modified liposomes containing (PI(3,5)P22), 162 
binding proteins were identified, 22 of which were novel and shared similar functional 
roles with known interacting partners, including vesicle-mediated transport machinery, 
GTPases, and protein kinases.  Collaboration with a bioinformatician revealed a novel 
motif, HRDIKP(E/S)N(I/L)LL, that was significant among the 162 novel (PI(3,5)P22) 
binding partners.  While the hypothesis was that this was not the site of PI binding, it 
represented a novel motif among PI-interacting proteins.  This approach exemplifies a 
beneficial improvement over traditional fluorescent liposomal nanovesicles, as it can be 
used on microarrays, and has promising applications in future high-throughput studies of 
protein-lipid interactions.  It is also important to note that with large studies such as this, 
it is crucial to have strong relationships with bioinformaticians to aid in the analysis of 




 Jones and colleagues developed a unique array that used protein domains instead 
of full-length proteins in order to investigate protein-peptide interactions deemed 
important in the ErbB family of receptors (Jones et al., 2006).  The array was printed with 
106 Src homology 2 (SH2) and 41 phosphotyrosine binding (PTB) domains, along with 
several tandem domains.  Arrays were incubated with 61 peptides representing tyrosine 
phosphorylation sites on the four ErbB receptors.  In order to quantitatively measure the 
protein-peptide interactions, eight concentrations of each peptide (between 10 nM and 5 
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mM) were tested, leading to the following insights: (1) the study of these interactions in a 
non-competitive format revealed high-affinity binding sites for both SH2 and PTB 
domain, but do not imitate the consensus recognition sequences; (2) ErbB2 recruitment 
sites are more promiscuous than any of the other receptors; (3) when comparing the 
highest-affinity interactions, the proteins that bind to EGFR comprise a small subset of 
those that bind to ErbB3; and (4) at high concentrations of EGFR and ErbB2, the binding 
becomes much more promiscuous, which may contribute to the high oncogenic potential 




 Another common application of protein microarrays is in the characterization of 
protein-DNA interactions (PDIs).  One of the earliest studies screened novel DNA-
binding proteins by probing the yeast proteome microarray with fluorescently labeled 
yeast genomic DNA (Hall et al., 2004).  Greater than 200 proteins were identified, and 
half of those were not previously known to bind DNA.  In order to determine whether the 
novel DNA-binding proteins were not artifacts (i.e. they nonspecifically bound in vitro, 
but not in vivo), the group tested eight novel proteins by using ChIP/chip.  The proteins of 
interest were tagged with 13 c-Myc epitopes at the C-terminal before treatment with 
formaldehyde to cross-link the protein to the potentially bound chromosomal DNA.  The 
Myc-tagged protein was then immunoprecipitated from the cell lysates, where the DNA 
was labeled with Cy5.  Five of the eight proteins showed no enrichment in any particular 
DNA loci, but three proteins (Mtw1, Dig2, and Arg5,6) were found to be specifically 
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associated with DNA loci in vivo.  The most important of which was Arg5,6, which is a 
single yeast gene that encodes two enzymes involved in arginine biosynthesis.  And while 
Mtw1 and Dig2 bound to multiple loci, Arg5,6 only bound to one specific loci found in 
both nuclear and mitochondrial chromatin.  Deletion of Arg5,6 altered the transcript 
levels of both nuclear and mitochondrial target genes, signifying that metabolic enzymes 
can directly regulate eukaryotic gene expression. 
Though shared genomic DNA can be used as probes, individually synthesized 
short DNA motifs can also be used as probes to interrogate the entire yeast TF repertoire 
immobilized on a glass slide.  Indeed, the Snyder and Johnston groups were the first to 
establish this approach as reported in a PNAS paper in 2006 (Ho et al., 2006).  Using a 
microarray containing 282 known yeast TFs, they were able to identify interactions with 
75 evolutionarily conserved DNA motifs.  Again, over 200 PDIs were identified, with 
greater than 60% of them previously unknown.  It was shown that 15 of the proteins 
bound almost all of the DNA probes non-specifically, while 62 proteins bound to at least 
one probe.  Further analysis identified Yjl103p as a novel DNA-binding protein and the 
DNA binding motif was found to be CGGN8/9CGG.  In order to obtain the target genes 
for this transcription factor, Yjl103p was either overexpressed or deleted before gene 
expression profiling.  Over 500 genes were differentially expressed with overexpression, 
many of which were involved with carbohydrate metabolism, stress response, or 
oxidative phosphorylation.  This was one of the first transcriptome-wide studies 
performed on an entire organism and paved the way for the analysis of the human 
transcriptome.   
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 Following up on the yeast transcription factor study from Ho et al., Hu and 
colleagues undertook a large-scale analysis of human PDIs using a protein microarray 
composed of 4,191 unique human proteins in full-length (henceforth known as the TF 
array), including approximately 90% of the annotated TFs and a wide range of other 
protein categories, such as RNA-binding proteins, nucleotide-binding proteins, 
transcription co-regulators, mitochondrial proteins, and protein kinases (Hu et al., 2009).  
The protein microarrays were probed with 400 predicted and 60 known DNA motifs and 
a total of 17,718 PDIs were identified.  Many known PDIs and a large number of new 
PDIs for both well characterized and predicted TFs were recovered, and new consensus 
sites for over 200 TFs were determined, which doubled the number of previously 
reported consensus sites for human TFs.  Unexpectedly, over 300 proteins that were 
previously unknown to specifically interact with DNA showed sequence-specific PDIs, 
suggesting that many human proteins may bind specific DNA sequences as a 
moonlighting function.  To further investigate whether the DNA-binding activities of 
these unconventional DNA-binding proteins (uDBPs) were physiologically relevant, in-
depth analysis was carried out on a well-studied protein kinase, Erk2, to determine the 
potential mechanism behind its DNA-binding activity.  Many in vitro and in vivo assays 
were performed, including electrophoretic mobility shift assays (EMSAs), luciferase 
assays, mutagenesis studies, and chromatin immunoprecipitation (ChIP).  These studies 
showed that the DNA-binding activity of Erk2 was independent of its protein kinase 
activity and it acts as a transcription repressor of transcripts induced by interferon gamma 
signaling.  Other than Erk2, many other uDBPs showed sequence-specific DNA-binding 
activity, and many of their consensus sequences are highly similar to those recognized by 
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annotated TFs.  This suggests that moonlighting functions of uDBPs based on their 
sequence-specific DNA-binding activity may be a widespread phenomenon in humans.   
Using the same approach, new proteins that may carry enzymatic activity in DNA 
repair can be discovered.  A bacterial proteome microarray composed of 4,256 proteins 
encoded by the E. coli K12 strain (≈99% coverage of the proteome) was developed by 
Chen and colleagues (Chen et al., 2008).  In order to identify proteins involved in DNA 
damage recognition, end-labeled, double stranded (ds) DNA probes containing abasic or 
mismatched base pairs were used.  Two proteins of unknown function, YbaZ and YbcN, 
were identified as binding with high affinity to abasic sites and mismatched sites, 
respectively.  Both of these proteins were shown to be base-flipping through the use of a 
2-aminopyrine (Ap)-modified DNA approach.  The fluorescence of 2-Ap is quenched 
when properly paired within the duplex, but the fluorescent intensity increases 
dramatically when flipped into an extrahelical conformation.  An increase of more than 
1,000-fold was observed for both proteins.  By probing the same proteome array with 
purified YbaZ, it was also found that YbaZ tightly interacts with the type IV helicase 




 It was long thought that RNA was only used for translation (mRNA, rRNA, and 
tRNA), but with the discovery of over 20 types of RNA, many have been characterized 
and shown to have a wide variety of functions in biology.  Long non-coding RNAs 
(lncRNAs) are most commonly thought as precursors to short RNA fragments, such as 
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microRNAs.  However, recent studies have shown that some of these lncRNAs can be 
several kilobases in length, and can be conserved extensively at the nucleotide level 
(Guttman et al., 2009).  Like microRNA, some lncRNAs block gene expression by 
antisense base pairing, but many act in cis by regulating mRNA transcription.  This is 
achieved by modifying heterochromatin formation near genomic loci.  Nonetheless, there 
have been relatively few lncRNAs functionally characterized, especially those which 
appear to act in trans to regulate gene transcription.  While there are existing methods 
available to study protein-RNA interactions, they are laborious and require large amounts 
of cell material.  Protein microarrays provide a unique and high-throughput platform 
from which these interactions can be quickly identified.   
Rapicavoli and colleagues were among the first to do so when they sought to 
further characterize the long non-coding RNA Six3OS, which is co-expressed with the 
homeodomain factor Six3 (Rapicavoli et al., 2011).  Six3 plays a pivotal role in 
mammalian eye development, where it regulates both early eye formation and cell 
specification to the postnatal retina.  Utilizing a human protein microarray, they were 
able to demonstrate that both mouse and human Six3OS was able to bind to five proteins, 
including Eya1, a homologue of the eyes absent gene of Drosophila, and Ezh2, a 
chromatin remodeling enzyme.  It was proposed that Six3OS modulates the expression of 
Six3 target genes by acting as a transcriptional scaffold that recruits histone modifying 
enzyme complexes, acting in a trans manner to do so.   
 More recently, a microarray containing more than 9,400 human proteins was used 
as a platform to identify binding interactions between proteins and 10 full-length coding 
and noncoding RNAs (Siprashvili et al., 2012).  The 137 protein-RNA interactions 
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discovered were enriched for known human RNA binding domains, including RRM, 
RBD, K homology domains, and zinc finger motifs.  One such protein, Staufen 1 (Stau1), 
was identified as a binding target of TP53 mRNA.  Using in vivo RNA-pulldown assays, 
they were able to show that Stau1 bound sense-TP53 mRNA, but not control mRNA.  
This was validated using reciprocal pull-down experiments.  Further characterization 
showed that Stau1 binding to TP53 RNA aided in maintaining its RNA levels during 
transcriptional blockades.   
 
Protein-small Molecule Interactions 
 
 Protein microarrays have also been shown to be useful in discovering new drug 
molecules and drug targets.  Rapamycin is a small molecule drug that can induce a 
starvation response and inhibit cell growth through its target TOR (target of rapamycin), 
a highly conserved protein kinase regulating cell proliferation and metabolism, both in 
yeast and in humans.  Huang et al. identified small-molecule inhibitors of rapamycin 
(SMIRs) and small molecule enhancers of rapamycin (SMERs) (Huang et al., 2004).  
They obtained the binding partners of two SMIRs, SMIR3 and SMIR4 by probing the 
entire yeast proteome with biotinylated versions of the SMIRs, and two targets for 
rapamycin inhibition were identified.  The first, Tep1p, is a homolog of the mammalian 
PTEN tumor suppressor; the second is Ybr077cp (Nir1p), a protein previously with no 
known function.  Both Nir1p and Tep1p were shown to associate with PI(3,4)P2, which 
suggests a novel mechanism by which phosphatidylinositides might modulate targets of 
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the rapamycin pathway and the ability of protein microarrays to identify specific protein-
small molecule interactions.     
 Polyanions are a particular class of proteins with considerable negative charge 
and are hypothesized to be involved in intracellular organization, protein stabilization and 
folding, and protein transport.  Salamat-Miller et al. used the yeast proteome array to 
probe for binding partners of well-characterized polyanionic proteins: actin, tubulin, 
heparin, heparin-sulfate, and DNA (Salamat-Miller et al., 2006).  By using biotinylated 
versions of these five polyanions, 893 polyanion-binding proteins (PABPs) were 
identified.  The polyanions and their binding partners were shown to form a network 




 One of the integral post-translational modifications involved in cellular membrane 
formation is glycosylation.  Proper glycosylation is critical in dictating proper 
conformation of many membrane proteins, retaining stability of some secreted 
glycoproteins, and facilitating cell-cell adhesion.  The yeast proteome array was used to 
further examine the roles of protein glycosylation in yeast (Kung et al., 2009).  Since the 
proteins were all purified in their native host, they were expected to maintain most of 
their PTMs.  To that end, the arrays were probed with two fluorescently labeled lectins: 
Concanavalin A (ConA), which recognizes mannose, and Wheat-Germ Agglutinin 
(WGA), which recognizes N-acetylglucosamine (GlcNAc).  Two separate yeast proteome 
arrays were used in this experiment.  The first was the aforementioned array used in 
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many of the previously discussed studies developed by Zhu et al. that used a GST affinity 
tag on the N-terminal and contained ≈5,800 yeast proteins.  The second array contained 
≈5,600 yeast proteins with a C-terminal Protein-A IgG-binding domain and was 
developed by Gelperin and colleagues (Gelperin et al., 2005).  There is an important 
distinction between these two arrays, especially as it pertains to glycoprotein signaling.  
Proteins that are anchored in the membrane at the C-terminal (and some type II proteins) 
are optimal for the N-terminal tagged array (Zhu) because the signaling sequence and 
transmembrane domains are present at the C-terminal and are unlikely to be effected by 
an N-terminal tag (e.g. cytochrome b5 and the SNARE proteins).  In contrast, proteome 
chips with C-terminal protein fusions (Gelperin) are optimal for studying type-I, and 
most of type-II and type-III membrane proteins that are glycosylated through the 
secretory pathway; the signaling and modifications with N-linked glycans occur at the N-
terminal and would be hindered by an affinity tag at the N-terminal.  ConA and WGA 
identified 124 and 174 proteins, respectively, in the N-linked array and ConA and WGA 
identified 236 and 142 proteins, respectively, in the C-linked array.  In total, 534 proteins 
were identified, 406 of which were previously not known to be glycosylated.  Gene 
ontology analysis identified enrichment in proteins from the secretory pathway, TFs, and 
other mitochondrial proteins.  These mitochondrial protein targets were further examined 
by treating yeast cell cultures with tunicamycin, an inhibitor of N-linked protein 
glycosylation.  Two of the four mitochondrial proteins identified showed partial 
distribution to the cytosol and reduced localization to the mitochondria, suggesting a new 
role of protein glycosylation in mitochondrial protein function and localization.   
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 Another approach to identifying protein-glycan interactions involves the inverse 
layout of the microarray.  A high-content lectin microarray consisting of 94 unique 
commercial lectins was fabricated and used to profile accessible surface glycans of 
mammalian cells (Tao et al., 2008).  Twenty-four human cell lines were labeled and 
applied to the microarray.  Each cell line was subjected to a binary algorithm that was 
developed to generate “glycan signatures,” resulting in hierarchical clusters based on 
each line’s accessible glycan composition.  By comparing the glycan profiles of a breast 
cancer cell line and its cancer stem-like cell derivatives, three lectins (LEL, AAL, and 
WGA) were found to specifically recognize MCF7 cells, but not the derivatives.  To 
further validate this results, the authors employed LEL-conjugated beads to purify away 
the normal MCF7 cells from the cancer stem-like cells (estimated as ≈0.1% in the cell 
population) in order to enrich for cancer stem-like cells.  Next, by using a mouse model 
to test the enrichment of the cancer stem-like cells, they were able to show that two 
weeks following injection of the LEL-depleted cancer stem-like cell enriched cultures, 
the average tumor size was greater than two-fold bigger than the control group injected 
with a similar number of normal MCF7 cells.  This study demonstrates the utility of using 
lectins on a microarray to identify novel cell surface markers on cancer stem-like cells, 
and the ability to enrich a sample for cancer stem-like cells. 




M), which can pose some difficulties when performing a cell-binding assay because low-
affinity interactions may be washed away from the immobilized lectins.  This is 
especially true when dealing with live cells.  To overcome these problems, several 
researchers have modified this technology to improve the strength of the binding 
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interactions.  One example involves the antibody-assisted lectin profiling (ALP) approach 
developed by Kuno et al. for detecting glycoproteins at low concentrations (Kuno et al., 
2009).  This method was used to analyze the glycan structures of the platelet aggregating 
factor hPod, which has been proposed to enhance the metastatic potential of glioblastoma 
cells.  The hPod protein complex was first enriched by immunoprecipitation, before 
incubation on a lectin microarray to identify its associated glycans.  The additional 
modification of the platform involves the use of an evanescent-field activated 
fluorescence detection system, which allows for a label-free, real time detection system.  
An evanescent field is generated within 200 nm of the solid surface, rendering the 
background signal so low that washing steps are not necessary.  Additional studies have 
shown that this system is by far the most sensitive detection system among lectin 
microarrays, reaching a reported detection limit in the 100 pM range (Uchiyama, 2006).   
 Finally, Li and Tao et al. reported a two-phase discovery and validation scheme 
improving the sensitivity of the lectin microarray in the study of prostate cancer 
biomarkers (Li and Tao et al., 2011).  The approach first involves pooling tissue samples 
from four groups in equal amounts (50 μg): normal, nonaggressive cancer, aggressive 
cancer, and metastatic cancer.  The discovery phase extracts prostate specific antigen 
(PSA) and membrane metallo-endopeptidase (MME) proteins from each tissue group 
using an anti-total PSA antibody and an anti-MME mAB, respectively.  The 
immunoprecipitated PSA and MME proteins were incubated on a lectin microarray, 
followed by detection of PSA and MME proteins using anti-PSA and anti-MME mAbs, 
respectively.  Comparison of signals between each group of pooled tissue revealed that 
the fraction of PSA that is O-glycosylated (as recognized by jacalin) or Neu5Ac-
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conjugated (as recognized by SNA) was highly elevated in aggressive prostate cancer and 
metastatic prostate cancer groups.  It was shown also that the fraction of MME that was 
modified by either GalNAx or GlcNac showed this elevation as well.  Confirmation of 
these finding were shown using an immunosorbent assay, in which PSA and MME were 
first captured on an ECL plate coated with anti-PSA and anti-MME mAbs, followed by 
detection with biotinylated lectins.  These studies show the power and adaptability of 
protein microarrays, even as they involve the detection of comparably weak protein-
glycan or protein-lectin interactions.   
Interaction Type Array Content Type of Probe Reference 
Protein-protein 60 EBV viral proteins Human protein Zhu et al., 2006 
 4,191 human proteins Viral protein Shamay et al., 2012 
Protein-lipid Yeast proteome PI(3,5)P22 liposomes Lu et al., 2012 
Protein-peptide 159 human SH2 and 
PTB domains 
Peptides Jones et al., 2006 
Protein-DNA 282 yeast TFs DNA motif Ho et al., 2006 
 4,191 human proteins DNA motif Hu et al., 2009 
Protein-RNA 9,400 human proteins Coding and 
noncoding RNAs 
Siprashvili et al., 2012 
 Yeast proteome BMV RNA loop Zhu et al., 2007 
Protein-small 
molecule 
Yeast proteome Small molecule 
inhibitors/enhancers 
of rapamycin 
Huang et al., 2004 
Protein-glycan Yeast proteome Lectins Kung et al., 2009 
 94 lectins Live mammalian cells Tao et al., 2008 
Table 3.  Applications of Microarrays to Detect Protein-binding Interactions. 
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Detection of Post-Translational Modifications 
 
Protein post-translational modifications (PTMs) are one of the most important 
mechanisms used by cells to directly regulate protein activity.  Hundreds of PTMs have 
been identified, and are enzyme-dependent and reversible, including protein 
(de)phosphorylation, (de)ubiquitylation, (de)SUMOylation, (de)acetylation, 
(de)nitrosylation, and (de)glycosylation.  Many labs have attempted to further understand 
the biological consequences of these PTMs, as it is important to identify downstream 
targets at a systems level.  “Shotgun” MS/MS techniques have been a workhorse in the 
identification of PTMs in mammalian proteomes.  However, this bottom-up approach 
does not identify the upstream enzymes responsible.  The functional protein microarray 
provides a fantastic platform for the investigation of the players responsible for this 




 Protein phosphorylation is one of the better-studied PTMs, and as such is 
considered one of the central players in most, if not all, cellular processes.  The 
application of protein microarrays to the study of phosphorylation was first demonstrated 
by Zhu et al. in 2000.  Seventeen different substrates were immobilized on a nanowell 
protein microarray, followed by individual kinase assays with 119 out of the 122 known 
yeast kinases (Zhu et al., 2000).  The in vitro phosphorylation was detected by using 
33
P-
γ-ATP as the phosphate donor in the kinase assay, and signal was acquired with either 
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film or a phosphorimager screen, which can be used to quantify the isotopic signal.  By 
using this approach, they were able to determine the kinase substrate specificity of the 
yeast kinome and identify a large number of tyrosine kinases.   
 As a follow up to this project, the Snyder group performed a large-scale 
“Phosphorylome Project” using the aforementioned yeast proteome arrays (Ptacek et al., 
2005).  Eighty-seven yeast kinases were purified and incubated with the yeast proteome 
microarrays in the presence of 
33
P-γ-ATP.  A total of 1,325 distinct protein substrates 
were identified, representing a total of 4,129 phosphorylation events.  Some observations 
were made immediately regarding the global kinase activity of yeast.  Most (73%) 
substrates were recognized by fewer than three kinases, signifying the strong specificity 
of kinases for their respective substrates.  Transcription factors were the largest class of 
proteins that were phosphorylated, supporting the regulatory role of phosphorylation on 
protein expression.  Further analysis provided a global network that connected kinases to 
their potential substrates, offering new opportunities to identify new signaling pathways 
and cross-talk between pathways.   
 The natural evolution of this research reached higher eukaryotes in early 2013 
when Newman et al. analyzed human kinase-substrate relationships (KSRs) using the TF 
microarray developed in the lab previously (Hu et al., 2009) which contained 4,191 
unique, full-length human proteins.  To date, approximately 2,000 human KSRs have 
been experimentally verified; that is, a known kinase has been shown to phosphorylate a 
known substrate.  This pales in comparison to the over 70,000 phosphorylated serine, 
threonine, and tyrosine residues that have been identified in vivo through mass 
spectrometry (MS/MS).  However, as mentioned before, simply knowing which residues 
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are modified does not give any insight to the pathways or even the direct upstream kinase 
that is responsible for the modification.  A new strategy, dubbed CEASAR (Connecting 
Enzymes And Substrates at Amino Acid Resolution), was employed to fabricate a high-
resolution map of human phosphorylation networks, connecting kinases to their 
immediate downstream targets (Newman et al., 2013).  The TF microarrays were 
incubated with 289 unique, active, and full-length human kinases in the presence of 
32
P-
γ-ATP.  These experiments yielded 24,046 phosphorylation events involving all 289 
kinases and 1,967 unique substrates to create a “rawKSR” dataset.  Using a Bayesian 
statistics model, the raw KSR dataset was refined by hypothesizing that the KSRs would 
be more physiologically relevant if they were known to share the same tissue specificity 
and sub-cellular localization, and if they were already known to interact from literature.  
A high-confidence dataset was created containing 3,656 refined KSRs (refKSRs) 
involving 255 unique kinases and 742 substrate proteins.  Finally, a combined (comKSR) 
dataset was created that included both the refKSR data and 719 known KSRs.  Validation 
studies in HeLa cell lines showed that 76% of tested KSRs showed some sort of kinase-
dependent change in the substrate (e.g. stabilization, degradation, or mobility shift).  At 
the same time, an integrated algorithm was developed, termed M3 (Motif discovery based 
on Microarray and MS/MS), to systematically identify phosphorylation motifs.  
Combining the large MS/MS datasets with the rawKSR and known KSR dataset, over 
13,000 of the 70,000 known phospho-sites identified by MS/MS were mapped to 1,644 
substrates.  Three hundred consensus motifs for 284 kinases were identified, representing 
55% of the human kinome.  Integrating the information from both the motif dataset and 
the in vivo phosphorylation site dataset into the comKSR dataset created a high-resolution 
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phosphorylation map connecting 230 kinases to 2,591 in vivo phosphorylation sites on 
652 substrates, and identifying over 3,600 new KSRs.  Using the newly generated 
phosphorylome map allowed an intermediate kinase to be identified in BCR signaling.  
Protein kinase A (PKA) was identified as both a substrate for Bruton’s tyrosine kinase 
(BTK) and a kinase for ARID3A, filling in a gap that had not been identified before.  The 
phosphorylations of both PKA and ARID3A were validated in vivo, and two 
phosphorylation sites on ARID3A that were predicted using M3 were verified.  It was 
shown that BTK phosphorylates and activates PKA during BCR signaling, which in turn 
leads to the stabilization of ARID3A upon phosphorylation by PKA.  Taken as a whole, 
this study represents a bright future of what functional protein microarrays can provide – 
a global understanding of cell signaling pathways through careful experimentation and 
bioinformatics.   
 Several smaller scale studies of kinase-substrate interactions have been reported 
as well.  For instance, Popescu et al. probed an array containing 2,158 Arabidopsis 
proteins with 10 Arabidopsis mitogen-activated protein kinases (MPKs) (Popescu et al., 
2008).  They identified 570 putative MPK phosphorylation targets, which were enriched 
in transcription factors involved in the regulation of development, defense, and stress 
response.  A commercially available human protein microarray comprised of 
approximately 3,000 individual proteins was used to identify substrates of cyclin-
dependent kinase 5 (Cdk5), a serine/threonine kinase that plays an important role during 
central nervous system development (Schnack et al., 2008).   
 As shown previously in the protein-RNA interaction applications, viral proteome 
microarrays are a very useful tool in the study of host-pathogen interactions.  In 2009, 
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Zhu and colleagues used an Epstein-Barr herpesvirus (EBV) protein microarray to 
investigate the function of an EBV-encoded protein kinase, BGLF4, via phosphorylation 
and binding assays (Zhu et al., 2009).  They identified a total of 23 BGLF4 substrates and 
interactors, including EBNA1, a protein that is essential for the replication and 
maintenance of the episomal EBV genome during latency.  The authors were able to 
show that BGLF4 acts as a negative regulator of EBNA1’s replication function and raised 
the possibility that the induction of BGLF4 kinase activity may provide a novel means of 




 Ubiquitylation is one of the most prevalent PTMs in eukaryotes and controls a 
variety of intracellular signaling events, but its regulatory mechanisms are largely 
unknown.  The use of protein microarrays represents a rapid and high-throughput method 
of identifying players in this pathway, and Gupta and colleagues did just that in 2007 
(Gupta et al., 2007).  Rsp5 is a well-characterized HECT-domain E3 ligase from yeast 
belonging to the Nedd4 family.  Using a commercial yeast proteome array for duplicate 
reactions, they were able to identify 40 high confidence Rsp5 substrates.  Rsp5 contains 5 
WW domains, which are known to bind to specific substrates by recognizing a (L/P)PXY 
sequence known as a PY motif.  Not surprisingly, 72% of these substrates contained at 
least one of these sequences.  Many of these were further validated in vitro and in vivo, 
indicating the fidelity of this assay.  After identification of the substrates of Rsp5, they 
again turned to the microarray to identify its binding partners by treatment with a 
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fluorescently labeled Rsp5, which again showed enrichment of proteins containing a PY 
domain.  From this, they were able to build both an interaction network and a substrate 
network. 
At the same time, Lu et al. used a protein microarray approach for the 
identification of Rsp5 substrates as well, but were able to further characterize two of the 
substrates (Lu et al., 2008).  Using the Zhu lab yeast proteome array, more than 90 new 
substrates were identified, and eight were validated as in vivo substrates of Rsp5.  
Characterization of one substrate, Rnr2 (a ribonucleotide reductase), revealed that Rsp5-
dependent ubiquitylation affects subcellular localization.  Heterozygous null mutants of 
Rnr2 correspond to hypersensitivity to DNA damage and treatment with the RNR 
specific inhibitor, hydroxyurea (HU).  After DNA damage, another member of the RNR 
family, Rnr4, is redistributed within cells, but it is not known whether it is due to a PTM.  
They were able to show that Rnr2’s localization was dependent on Rsp5, as it was 
localized to both the cystosol and nucleus in a wt strain, but only localized to the nucleus 
in an Rsp5 knockout strain.  Both of these previous studies highlight the power that 
protein microarrays can hold in the analysis of ubiquitylation.  
While each of the previous assays described were able to identify true in vivo 
interactions in an in vitro setting, one limitation is apparent, as none can mimic the 
precise cellular conditions used by these proteins in vivo.  This can lead to false positives 
due to the promiscuity of the applied protein, or false negatives due to some of the 
necessary co-factors being absent from the reaction mix.  The use of concentrated 
mammalian cell extracts in combination with protein microarrays can serve to identify 
PTM targets in a semi-in vivo setting while alleviating the challenge of analyzing a 
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complex mixture.  Merbl and Kirschner generated from HeLa S3 cells three cell extracts 
from the two distinct phases surrounding anaphase: the mitotic checkpoint (treated with 
nocodazole, which prevents mitotic spindle formation and checkpoint arrest), the 
anaphase release phase (treated with the E2 ligase UbcH10), and an anaphase release 
phase containing an APC (anaphase promoting complex) inhibitor as well as UbcH10 
(Merbl and Kirschner, 2009).  The synchronized cell extracts were incubated with 
Invitrogen’s Human ProtoArray (composed of 8,000 human proteins) and using the anti-
polyubiquitin antibody FK1, identified 132 polyubiquitylated proteins. The authors 
expected to recover substrates of APC and were able to identify 11 of the 16 known APC 
targets on the array, confirming the experimental design.  Validation studies performed in 
rabbit reticulocyte lysate confirmed the degradation/ubiquitylation of 7 novel APC 
substrates.  This study demonstrates the efficacy of using protein microarrays in 





 Acetylation of histone residues by histone acetyltransferases (HATs) and 
deacetylation by histone deacetylases (HDACs) has been shown to be a key regulator of 
chromatin structure and transcription.  While histones appear to be the dominant substrate 
for this modification, it has been hypothesized that many other non-histone proteins may 
be modified by these enzymes.  For example, the HAT Esa1, which is part of the 
essential nucleosome acetyltransferase of H4 (NuA4) complex, is the only vital HAT in 
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yeast, suggesting that it may target other non-histone proteins critical for survival.  Non-
histone substrates of the NuA4 complex were identified by Lin et al. by performing 
acetylation reactions on the yeast proteome microarrays (Lin et al., 2009).  Arrays were 
treated with purified NuA4 complex in the presence of 
14
C-Acetyl-CoA as the donor, and 
91 proteins were found to be readily acetylated.  Further validation of 20 targets revealed 
13 with Esa1-dependent acetylation in cells.  Phosphoenolpyruvate carboxykinase 
(Pck1p) was further characterized by mass spectroscopy, where acetylation was observed 
on Lys19 and Lys514.  Mutagenesis at these sites demonstrated that K514 acetylation is 
critical in enhancing the activity of Pck1p, resulting in a longer life span for yeast 




 S-nitrosylation is a unique PTM in that it is independent of enzyme catalysis, but 
is nonetheless an important one that affects a wide range of protein and cellular 
processes, including inflammation and protection from apoptosis.  Recently, Foster et al. 
developed a protein microarray-based approach to identify proteins reactive to S-
nitrosothiol (SNO), the donor of NO+ in S-nitrosylation (Foster et al., 2009).  S-
nitrosocysteine (CysNO), a highly reactive SNO, was added to a commercially available 
yeast microarray.  Nitrosylated proteins were detected using a modified biotin switch 
technique (BST), which converts an S-nitrosothiol into an S-biotinylated Cys.  The arrays 
were subsequently probed with an anti-biotin antibody, followed by a fluorescently 
labeled secondary antibody.  The top 300 proteins with the strongest signal were further 
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characterized and showed that proteins with active site Cys thiols residing at N termini of 
alpha helices or within catalytic loops were particularly enriched.  However, even among 
these protein families, there was significant variation in the S-nitrosylation, signifying 
that secondary structure or intrinsic nucleophilicity of Cys thiols was not sufficient to 
interpret the specificity of S-nitrosylation.  Further analyses revealed that NO-donor 




 Although many, if not most, proteins have been identified as phosphorylated on 
serine and threonine residues, modification by β-N-acetylglucosamine (O-GlcNAc) on 
serine and threonine residues has emerged as another fundamental regulatory mechanism 
in cell signaling.   O-GlcNAc cycling on proteins is mediated by two enzymes: O-
glycosyltransferase (OGT), which glycosylates S/T residues, and O-GlcNAcase (OGA), 
which hydrolyses S/T residues back to their native state.  Like phosphorylation, O-
GlcNAcylation can modify protein function, including kinase activity, turnover, protein-
protein interactions, subcellular localization, DNA affinity, and transcription activity.  
Dias et al. were the first to use a functional protein microarray to probe for O-GlcNAc on 
a large scale (Dias et al., 2012).  A commercially available kinase array was used which 
contained 152 full-length human kinases.  Using tritiated UDP-GlcNAc (UDP-
3
H-
GlcNAc) as the donor along with purified OGT, they were able to identify 42 kinases 
modified in vitro.  Further validations in HEK293 cells were performed that confirmed 
the modification occurs in vivo as well.  While phosphorylation is controlled in humans 
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by over 500 kinases and over 150 phosphatases, there is only one OGT and one OGA, 
suggesting that the specificity with which these enzymes react most likely involves other 
binding partners, and further studies will need to be performed in order to elucidate the 
breadth of this modification.   
PTM Studied Substrate Enzyme Reference 
Phosphorylation Yeast proteome Yeast kinases Ptacek et al., 2005; 
Zhu et al., 2000 
 3,000 human 
proteins 
Human CDK5 Schnack et al., 2008 
 Human TF array Human kinases Newman, et al., 
2013 
 Human proteome Human CK2 Tarrant et al., 2012 
Ubiquitylation Yeast proteome Ubiquitin E3 Rsp5 Lu et al., 2008 
SUMOylation Human  E3 RanGAP1 Oh et al., 2007 
Acetylation Yeast proteome NuA4 complex Lin et al., 2009 
 E. coli proteome PAT Thao et al., 2010 
S-nitrosylation Yeast proteome N/A Foster et al., 2009 
O-glycosylation Human kinases OGT Dias et al., 2012 






Profiling Monoclonal Antibody Specificity 
 
 Antibodies have widespread applications in proteomic studies, but some difficulty 
lies in producing antibodies with sufficient specificity.  Monoclonal antibodies (mAbs) 
are a better option than polyclonal antibodies for most applications, but tend to be much 
more expensive and can sometimes be too specific.  Protein microarrays offer a technique 
to be able to test the specificity of these antibodies.  After immunizing mice with live 
cells from human livers, Hu et al. isolated 54 hybridomas with binding activities to 
human cells and identified antigens for five mAbs by screening on a protein microarray 
consisting of 1,058 unique human liver proteins (Hu et al., 2007).  The five identified 
mAbs were subsequently used to characterize the expression profiles of their 
corresponding antigens in both normal liver cells and hepatoma cells.  Among them, 
eIF1A, an essential initiation factor in translation, was found to be present in normal 
hepatocytes, but not in any hepatoma cells, suggesting that liver carcinomas likely have 
suppressed translation.   
 In 2012, Jeong and colleagues used a similar approach combining immunization 
with live human cells and even larger microarray-based analysis to rapidly identify 
monospecific monoclonal antibodies (mmAbs) (Jeong et al., 2012).  The protein 
microarray used in this study is one of the largest to date, as it contains almost 17,000 
individually purified full-length human proteins.  When the monoclonal antibodies were 
used on this array and only recognized a single antigen, they could be identified as 
monospecific mAbs.  These antibodies were tested against their respective antigen and 
could be successfully identified in western blots (WB), successfully immunoprecipitate 
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endogenous antigen from homogenate, and successfully used in immunocytochemistry 
(ICC) in transfected human cell lines.  The specificity with which this approach created 
mmAbs was more useful (e.g. more applications – WB, IP, ICC/IHC) than many other 
commercially available sources.  For example, 66% of the mmAbs tested were IP-grade, 
compared to the commercial average of 18%.  Future studies may be able to use this 
approach to tackle the issues analytical microarrays possess by easily and rapidly 
producing highly specific mmAbs.   
 
1.6 Clinical Research Applications 
 
 As the basic research field continues to profit from protein microarrays, so does 
the clinical field.  The ability to more sensitively and rapidly screen patient samples 
against a large array of proteins inches us closer to what many consider the future of 
health care – personalized medicine.  While we certainly are not at the level yet, there is 
great promise shown in many of the studies that have arisen the last decade.  In this 
section, we will discuss three applications of protein microarrays in the clinical field: 




 One of the most rapidly growing applications in the field of clinical proteomics 
using protein microarrays is biomarker identification.  This was first used in traditional 
serology studies, which focused on diagnostic identification of antibodies in patient 
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serum samples.  These antibodies are produced as a part of the immune response to an 
infection, a foreign protein, or, in the case of autoimmune disease, against ones own 
proteins.  Using protein microarrays as a platform for potential antigens, researchers can 
identify autoantibodies with statistical significance and association with an infection or 
disease of interest.  Generally, the patient sera are first diluted (e.g. 1,000-fold) before 
incubation on a pre-blocked antigen microarray (e.g. protein microarray) and ending with 
a stringent washing step.  Then, positive signals are detected using anti-human IgG, IgM, 
or IgA antibodies conjugated to various fluorophores.  Compared to traditional serology 
techniques, such as ELISA, agglutination, precipitation, complement-fixation, and 
fluorescent antibodies, protein microarray-based profiling is much more sensitive, 
unbiased, and can be performed at a much higher throughput.  This next section will 
review four studies illustrating the history and development of protein microarrays in 




 The first viral proteome microarray was fabricated by Zhu et al. and consisted of 
every full-length protein and protein fragment encoded by the SARS coronavirus (SARS-
CoV) as well as proteins from five additional mammalian coronaviruses (Zhu et al., 
2006).  These microarrays were used to screen 400 Canadian serum samples that were 
collected during the 2002 SARS outbreak.  Included samples were those confirmed as 
SARS-CoV positive, other respiratory illness patients, and healthcare professionals.  
Antibody response was quantified by using both human IgM and IgG antibodies coupled 
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to different fluorophores.  In order to identify biomarkers, the serum samples were first 
clustered according to the relative signal intensities of all coronavirus proteins in an 
unsupervised fashion.  Two major groups were identified, which, when compared to 
clinical data, were largely correlated with either SARS-positive or SARS-negative sera.  
Five fragments of the SARS nucleocapsid protein (N protein) associated tightly with 
SARS infection, as well as one spike protein (S protein) fragment.  However, a few 
proteins encoded by other coronaviruses also displayed significant correlation.  In order 
to determine the best classifiers and classification model, two different supervised 
analysis approaches were applied; k nearest neighbor (k-NN), which measures the 
similarity between a new case and all known cases, and logistics regression (LR), a 
generalized linear regression for binary response.  The N protein of SARS-CoV and the S 
protein from both SARS-CoV and HCoV-229E were identified as the best classifiers.  
One useful feature of a serum test over a nucleic acid diagnostic test is that anti-pathogen 
antibodies can potentially be detected long after infection.  To that end, serum samples 
collected from SARS patients who recovered from respiratory disease (≈320 days after 
diagnosis) were used to probe the microarray, where positive signals were detected with 
both anti-human IgM and IgG antibodies.  The results showed that SARS N proteins 
could be readily recognized by human IgG and importantly, not by IgM antibodies.  
However, serum samples collected from Chinese patients immediately after fever was 
detected showed much stronger signal both in IgG and IgM profiling.  These results show 
that protein microarrays can be used to detect both early response anti-pathogen 
antibodies as well as late response antibodies long after infection.  This approach is 
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potentially applicable to all viruses and is expected to have a large impact on both 
epidemiological studies and clinical diagnoses.   
 
Humoral immune responses to herpesviruses 
 
 A similar approach has been used to profile humoral immune responses to two 
human herpesviruses, the Epstein-Barr virus (EBV) and Kaposi’s sarcoma-associated 
herpesvirus (KSHV).  While EBV is a ubiquitous human herpesvirus, KSHV has a much 
more restricted seroprevalence.  Both viruses have been shown to be associated with 
malignancies and also display an increased frequency in individuals who are also infected 
with human immunodeficiency virus type 1 (HIV-1).  To investigate humoral immune 
responses, a protein microarray consisting of 174 EBV and KSHV full-length proteins 
was generated by the Zhu and Hayward groups (Zhu et al., 2009; Zheng et al., 2011).  
Plasma antibody responses to EBV and KSHV were examined from healthy volunteers 
and patients with B-cell lymphoma, or with AIDS-related Kaposi’s sarcoma or 
lymphoma.  Apart from detecting IgG responses from known antigens, the tegument 
proteins ORF38 (KSHV), BBRF (EBV), BGLF2 (EBV), and BNRF1 (EBV), and the 
EBV early lytic proteins BRRF1 and BORF2, were also detected.  IgA responses to EBV 
EBNA1 and viral capsid antigens have been used as a diagnostic tool for nasopharyngeal 
carcinoma for years, but the same IgA response was also found in healthy and HIV-
infected patients.  Comparing the IgG and IgA responses showed that IgA responses were 
much higher against BCRF1, BRRF2, and LMP2A.  This study demonstrates that even 
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plasma can be used for biomarker identification and that other immunoglobulin isotypes 
such as IgA are worth considering when studying immune response.   
 
E. coli proteome microarrays for IBD diagnosis 
 
 Crohn’s disease (CD) and ulcerative colitis (UC) are chronic, idiopathic, and 
clinically heterogeneous intestinal disorders that are collectively known as inflammatory 
bowel disease (IBD).  Although IBDs have been implicated in autoimmune disease, 
antibodies against microbes have been seen in the sera of IBD patients, some of which 
have been used as biomarkers for diagnosis and prognosis of the disease.  Using the same 
E. coli K12 protein microarray that was used to study protein-DNA interactions 
mentioned earlier, Chen et al. decided to profile serum samples collected from CD and 
UC patients (Chen et al., 2009).  The proteome array was screened using individual 
serum from healthy controls (n=39) and clinically well-characterized patients with CD 
(n=66) and UC (n=29).  To their surprise, among the 417 E. coli proteins that were 
differentially recognized by serum antibodies from healthy controls and either IBD 
patient, 169 proteins were identified as highly immunogenic in healthy controls, 186 were 
identified as highly immunogenic in CD patients, but only 19 proteins were identified as 
highly immunogenic in UC patients.  Through statistical analysis, they were able to 
identify two sets of serum antibodies as novel biomarkers for distinguishing CD from 
healthy controls (accuracy, 86±4%; p <0.01) and CD from UC (accuracy, 80±2%; p 
<0.01).  This was the first demonstration of using proteome microarrays for the discovery 
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of novel serological markers, as well as the first to examine human immune responses to 
the entire proteome of a microbial species in a disease context. 
 
Autoantigen discovery for Autoimmune Hepatitis (AIH) 
 
 A microarray consisting of individually purified human proteins would seem an 
ideal tool for the discovery of new autoantigens associated with autoimmune disease.  
Autoimmune hepatitis (AIH) is a chronic necroinflammatory disease of the human liver 
with little known etiology.  Although the detection of non-organ-specific and liver-related 
autoantibodies using immunoserological approaches have been widely used for diagnosis 
and prognosis, these traditional autoantigens, such as anti-SMA (smooth muscle 
autoantibodies) and anti-ANA (antinuclear autoantibodies) are often mixtures of very 
complex biological materials.  Identification and characterization of these autoantigens is 
dependent on their unambiguous and accurate detection, which is not possible using the 
traditional means.  To address this, Song and colleagues created a human protein 
microarray of 5,011 non-redundant proteins that were expressed and purified from yeast 
(Song et al., 2010).  In order to make this technique feasible in a clinical application, the 
cost of performing such an assay has to be considered, as a single human protein array 
with 9,000 proteins can cost upwards of $1,000.  Therefore, a two-stage strategy was 
employed to limit costs in identifying new biomarkers in AIH.  Phase I consists of rapid 
selection of candidate biomarkers, which are then validated in a smaller array in Phase II.  
In Phase I, 30 AIH and 30 control serum samples were obtained and individually used to 
probe the human protein microarrays at a 1,000-fold dilution.  This was followed by 
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detection using a Cy5-conjugated anti-human IgG antibody.  After statistical analysis, 11 
candidate autoantigens were found.  In order to validate the candidates, the 11 proteins 
and 3 positive controls were purified again to use in the production of a large number of 
low-cost small arrays for Phase II validation.  These new, smaller arrays were 
sequentially probed with the serum samples used in Phase I as well as from serum 
samples obtained from an additional group of patients consisting of 22 AIH, 50 primary 
bilary cirrhosis (PBC), 43 hepatitis B (HB), 41 hepatitis C (HC), 11 system lupus 
erythematosus (SLE), 11 primary Sjögren’s syndrome (pSS), and 2 rheumatoid arthritis 
(RA) samples.  Twenty-six serum samples from patients with other types of severe 
disease and 50 samples from healthy subjects were used as negative controls.  From these 
Phase II studies, three new antigens, RPS20, Alb2-like, and dUTPase, were identified as 
highly AIH-specific biomarkers with sensitivities of 47.5%, 45.5%, and 22.7%, 
respectively.  These were further validated with additional AIH samples in a double-blind 
design, and were also able to demonstrate that these new biomarkers could be easily 
applied to canonical ELISA-based assays for clinical diagnosis and prognosis. 
 This study represents a novel paradigm in biomarker identification using protein 
microarrays for three reasons.  First, a manageable number of candidate biomarkers can 
be quickly identified at a low cost because fewer expensive microarrays are required for 
Phase I.  Second, by using a smaller microarray consisting only of selected candidate 
proteins, the validation step can be quickly carried out in higher throughput with a much 
lower cost.  This is the crucial step in the validation of these markers if one is to avoid an 
“overfitting” problem that can arise when a candidate list is smaller than 40, which is 
likely the case for many of these applications.  Overfitting becomes an issue when a 
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statistical model describes random error instead of identifying a relationship.  If a system 
is excessively complex, as is the case with most biomarker identification screens, then 
there are too many individual-to-individual variations relative to the number of samples 
used, leading to poor predictive performance.  Therefore, testing in an additional, larger 
cohort using a double-blind protocol is an effective way to overcome this issue.  Third, 
the author developed an ELISA-based assay to examine the performance of the newly 
identified biomarkers, serving as a translational step towards clinical practice.   
 Several other studies have employed pathogen protein microarrays to profile 
serological responses following infection as well, including bacterial and viral arrays 
used for biomarker identification in various infectious diseases (Liang et al., 2011; Vigil 
et al., 2011; Luevano et al., 2010; Doolan et al., 2008).  While these studies have clearly 
demonstrated the power of protein microarrays in the identification of potential 
biomarkers, several shortcomings are repeatedly seen in these studies.  For example, 
many of these arrays were fabricated using proteins translated in E. coli lysates without 
purification.  Because these proteins are contaminated with unwanted E. coli proteins, the 
sensitivity of the assay is likely reduced due to their high immunogenicity, although using 
E. coli lysates to block the array alleviates this problem to a degree.  More importantly, 
many of the biomarkers identified in these studies were not validated with additional 








 Another emerging application for protein microarrays in clinical proteomics is the 
unbiased, proteome-wide survey of important players involved in pathogen-host 
interactions.  The identified factors, whether encoded by either a pathogen or a host, have 
the potential to be developed into potent therapeutic targets.  This strategy is particularly 
useful for investigating virus-host interactions because after entering the host cells, the 
viral genome and its encoded proteins are in direct physical contact with the host’s 
biological materials.  This section will cover three ways in which these interactions can 
be investigated: RNA-protein interactions, enzyme-substrate relationships, and protein-
protein interactions.   
 
BMV RNA and Host Proteome Interactions 
 
The yeast proteome array was used to identify host factors that can affect the 
replication of Brome Mosaic Virus (BMV), an RNA virus that infects plants, but can also 
replicate inside of S. cerevisiae (Zhu et al, 2007).  Previous studies had shown that this 
positive-stranded RNA virus encodes a tRNA-like structure at the 3’-end of its RNA 
genome, where a clamped adenine motif (CAM) is required for the packaging of its 
genome into the capsid.  To identify the necessary host proteins that could interfere with 
the viral packaging process, the yeast proteome arrays were incubated with a Cy3-labeled 
CAM-containing RNA stem-loop structure in the presence of a Cy5-labeled mutated 
CAM hairpin.  By taking the Cy3:Cy5 ratio, the top hits were identified and validated 
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using an in vitro gel-shift assay.  Two candidate proteins, Pseudouridine Synthase 4 
(Pus4) and the Actin Patch Protein 1 (App1), were further characterized in Nicotiana 
benthamiana.  Both were shown to reduce BMV plus-strand RNA accumulation 
modestly, but had a much greater effect on the ability of BMV to spread in plants.  Pus4 
was also shown to prevent the encapsidation of the BMV RNA and reassembly of 
virions, providing a regulatory link between CAM-containing RNA motifs and 
encapsidation.  This is yet another example of the considerable versatility of protein 
microarrays.  Not only can they be used to study prokaryotic and eukaryotic interactions, 
but viral interactions as well, in an unbiased and systematic manner.   
 
Host Phosphorylome of Virus-Encoded Kinases 
 
 Viruses have been very successful in exploiting their hosts in developing their 
own “arsenal,” sometime using both host DNA and proteins in the process.  
Understanding the method by which the virus interacts with the host machinery is critical 
in developing effective antivirals.  The human α, β, and γ herpesviruses differently infect 
tissues and cause distinct diseases, ranging from mild cold sores to pneumonitis, birth 
defects, and even cancers.  However, they each confront similar challenges in infecting 
their hosts, namely reprogramming cellular gene expression, sensing and modifying cell-
cycle progression, and reactivating the lytic life cycle to produce new virions and spread 
infection.  Across the herpesvirus family, many orthologous serine/threonine kinases are 
conserved that are involved in replication of the viral genome during the lytic life cycle.  
Therefore, many have postulated that if there are any shared substrates between these 
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orthologous viral kinases, the targeted host proteins critical for viral replication would be 
revealed and aid in distinct and effective antiviral targets.   
 In testing this hypothesis, Li and colleagues purified four orthologous kinases 
encoded by EBV, KSHV, HCMV (human cytomegalovirus), and HSV-1 (herpes simplex 
virus 1) and incubated them on a human protein microarray (Li and Zhu et al., 2011).  
They identified 110 shared substrates and applied Gene Ontology (GO) and STRING 
analyses (a database of known and predicted protein-protein interactions – http://string-
db.org/) to these candidates, finding a highly connected cluster of 15 proteins.  
Surprisingly, these proteins were all shown to be associated with the DNA damage 
response (DDR) pathway.  The host DDR has been known to be an important player for 
many viruses, including human herpesviruses, and is also relevant to virus-induced 
tumorigenesis (Nikitin et al., 2012).  To further narrow down the potential players in this 
pathway, it was reasoned that an upstream master regulator of the pathway would be a 
likely target.  After literature searches, Tat-interactive protein 60 (TIP60) emerged as an 
excellent candidate for four reasons: (1) TIP60 is further upstream in the DDR pathway 
than the other candidates; (2) it serves as a master regulator in DDR by acetylating ATM 
and initiating its autophosphorylation activity; (3) it is a histone acetyltransferase, and 
therefore can regulate chromatin dynamics through histone acetylation; and (4) it has 
been implicated in other viruses.  When TIP60 was knocked down in EBV-infected B-
cells, EBV’s lytic replication was greatly reduced.  Next, the authors performed a series 
of cell-based assays showing that during EBV replication, TIP60 activation by the 
BGLF4 kinase triggers EBV-induced DDR and mediates induction of viral lytic gene 
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expression.  Efficient lytic replication was also shown to be dependent on TIP60 in 
KSHV, HCMV, and HSV-1.   
 This work illustrates that high-throughput, unbiased approaches for the 
identification of conserved viral host targets show great potential for novel therapeutic 
antiviral targets.  Treatment of herpesvirus is limited to very few drugs due to viral 
escape mutants that arise from extensive use, rendering these kinases attractive targets for 
future studies.  Like all drug studies, development of effective drugs requires extensive 
knowledge of cellular targets.  This novel “common substrate identification” approach 
using microarrays can aid in the design of new assays for new and broadly effective anti-
herpesvirus therapeutics.   
 
LANA Interactome Analysis Reveals a Role in Telomere Shortening 
 
 While we have already discussed using protein microarrays to measure protein-
protein interactions, it can also be specifically used to profile interactomes between a 
pathogen and a host.  Recently, Shamay and colleagues examined interactions between 
the KSHV-encoded virulent factor, LANA, and a human host using the transcription 
factor microarray described before (Shamay et al., 2012).  LANA is an essential 
participant in KSHV genome replication and dysregulated cell growth in latently infected 
cells.  Its interactions with host proteins have been extensively studied using a variety of 
techniques (including Y2H, GST affinity, IP assays, and HPLC-MS/MS), but each 
approach identified a different group of proteins.  This study used a FLAG-tagged LANA 
to identify 61 potential binding partners, many of which were novel.  Further validations 
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confirmed 8 of 9 by co-immunoprecipitation and included TIP60, protein phosphatase 2A 
(PP2A), replication protein A (RPA) and the DNA-repair protein XPA.  Although human 
papillomavirus (HPV) E6, HIV-1 TAT, and HCMV pUL27 interact with TIP60 to induce 
its degradation, LANA-associated TIP60 retained its HAT activity and showed increased 
stability.  This finding mirrors what was described in the previous section that showed 
TIP60 plays a positive role in KSHV lytic replication.  The identification of LANA as an 
RPA binding partner suggests that it may also have a role in the replication of cellular 
telomeric DNA.  To test this, the authors performed ChIP assays using anti-RPA1 and –
RPA2 antibodies and primers specific for the telomeric regions of DNA.  They found that 
when LANA was present, RPA1 and RPA2 recruitment to telomeres was inhibited, but 
had no impact on the protein levels of the RPA complex, which implicated LANA as a 
factor in telomere length.  Using Southern blots to analyze terminal restriction fragments 
showed that the length of telomeres was shortened by at least 50% in both LANA-
expressing endothelial cells and KSHV-infected primary effusion lymphoma cells.  
Although it was shown that LANA effects telomere length, many more questions 
regarding its role need to be answered to fully understand how it is used by KSHV.   
 
SUMO-EBV Interactome Reveals a New Mechanism of EBV Lytic Replication 
 
 Inversely, a human factor of interest can be used to probe a virus protein 
microarray to identify crucial viral factors.  The small ubiquitin-related modifier (SUMO) 
pathway is similar to the ubiquitin pathway because it involves a series of sequential 
enzymatic reactions to conjugate SUMO to lysine residues on substrate proteins.  It has 
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been shown that both latent and lytic EBV proteins can interact with the SUMOylation 
pathway, with non-covalent interactions occurring between SUMO and EBV proteins via 
a SUMO interaction motif (SIM).  In order to systematically identify EBV proteins that 
bind to SUMO, Li et al performed binding assays with human SUMO2 using the 
previously described EBV proteome microarray (Li et al., 2012).  Eleven proteins were 
identified, including the conserved viral kinase BGLF4.  Mutations at putative SIMs 
within BGLF4 at both the N- and C-termini changed the intracellular localization from 
the nucleus to the cytoplasm.  If mutations were made at only the N-termini, localization 
remained mostly in the nucleus, and localization was in both the cytoplasm and the 
nucleus when mutations were made at only the C-termini.  BGLF4 was shown to inhibit 
the EBV lytic cycle transactivator ZTA by abolishing its SUMOylation.  The inhibition 
was shown to be dependent on both BGLF4 SUMO binding and BGLF4 kinase activity.  
Global SUMOylation was suppressed by active BGLF4, but not by SIM or kinase-dead 
BGLF4 mutants.  Furthermore, interaction of BGLF4 with SUMO was required to induce 
DDR and enhance extracellular viral production during EBV lytic replication.   
 
Identification of Novel Streptococcal Proteins that Bind Human Ligands 
 
 Pathogen-host interactions are not just limited to viruses, and the need to find 
novel antibiotics is becoming increasingly pertinent.  Therefore, it is not surprising that 
protein microarrays have been utilized to identify bacterial pathogen-host interactions.  
Margarit and colleagues used microarrays to identify proteins expressed by two species 
of the streptococcus gram-positive bacteria, Streptococcus pyogenes and S. agalactiae, 
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that interact with human factors known to mediate pathogenesis (Margarit et al., 2009).  
A bioinformatics approach was first used to predict 200 proteins that are present on the 
cellular surface, and therefore are more likely to paly a role in infection.  The human 
probes were also carefully selected because of their known roles in colonization and 
infection: fibronectin, fibrinogen, and C4 binding protein.  Treating the array consisting 
of the 200 predicted proteins with these probes identified 17 of the 20 known 
interactions, as well as 8 novel contacts, which were further validated using far-western 
blot analysis.  Three of the novel proteins identified were related, termed fib proteins, and 
using domain mapping, the authors were able to identify regions of these proteins that 
were required for their interaction with the human ligands.  Subsequent assays of sera 
from patients with S. agalactiae showed high titers of Fib-specific antibodies, indicating 
their relative abundance during infection.  There is hope that future studies will be able to 
determine the exact role of these proteins in infection and if they are suitable drug targets 
for Streptococcus infections.   
 Taken together, these studies show the tremendous power of protein microarrays 









Disease Type Disease Substrate Reference 
Infectious SARS infection 82 viral proteins Zhu et al., 2006 
 B cell lymphoma/ AIDs-
related Kaposi’s 
lymphoma 
174 EBV and KSHV 
viral proteins 
Zheng et al., 
2011 
 Rabbit model of the 
plague 
149 proteins from 
Yersinia pestis 
Li et al., 2005 
 Brucellosis 3,046 proteins 
expressed in lysates 
Liang et al., 2011 
 Cervical carcinomas 154 proteins from 13 
papillomavirus 
Luevano et al., 
2010 
 Streptococcus infection 201 viral proteins 
from 2 strains 
Margarit et al., 
2009 
Autoimmune Inflammatory bowel 
disease 
E. coli arrays with 
4,179 proteins 
Chen et al., 2009 
 Autoimmune hepatitis 5,011 human 
proteins 
Song et al., 2010 
 Primary biliary cirrhosis 17,000 human 
proteins 
Hu et al., 2012 
 Sjögren’s syndrome 8,000 human 
proteins 
Hu et al., 2011 







 Over the last five years, rapid development of genome-wide sequencing (e.g. 
next-gen sequencing) has revealed the heterogeneous nature of tumors, but clinical 
diagnosis is largely still dependent on morphological patterns (Parsons et al., 2011; 
Gerlinger et al., 2012).  Although tumors have indistinguishable morphology, they often 
have vastly different clinical outcomes, so the composition of this heterogeneity needs to 
be better understood before more effective therapies can be developed.  An 
individualistic therapy approach is thought to be the future of cancer research, so a new 
class of proteomic profiling technologies will have to be developed in order to meet this 
need.  Protein microarrays have shown the potential to meet this need and have proven 
useful in profiling the functional state of tumors and for cancer biomarker identification.   
 
Reverse Phase Protein Microarrays in Cancer Biology 
 
 One common approach that has been used to determine the status of signaling 
pathways in tumor cells is based on an immunoblot assay that uses antibodies to 
recognize phosphorylated proteins.  Haab et al was the first to scale this up to high 
throughput when they developed an antibody array, spotting individual commercial 
antibodies onto glass slides in high density (Habb et al., 2001).  This technology allows 
for the simultaneous detection of multiple antigens presented in a complex biological 
sample, such as cells, tissues, and body fluids (Borrebaeck et al., 2009; Haab, 2003).   
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 In 2001, Paweletz and colleagues coined the term “reverse phase protein 
microarray” to describe an array in which lysates of cells or tissues are immobilized on 
the array surface rather than antibodies (Paweletz et al., 2001).  By using phosphoprotein-
specific antibodies, these arrays can be used to interrogate the phosphorylation state 
present in cell lysates from tumor samples.  Many clinical trials are currently ongoing 
that are utilizing these arrays (Muellet et al., 2010).  A large hurdle for most clinical trials 
and diagnostic tests is the minimal amount of sample that is available from the patients.  
Unobtrusive methods are few and far between, so these arrays are a welcome approach 
because not only can it allow for the evaluation of multiple components of a signaling 
pathway, very little sample is required for microarray fabrication.  These samples can be 
printed on a series of identical arrays and analyzed in parallel using commercially 
available phoshoprotein-specific antibodies.   
 Petricoin and coworkers obtained 59 cell lysate samples from the Children’s 
Oncology Group Intergroup Rhabdomyosarcoma Study (IRS), and fabricated them into a 
reverse phase microarray (Petricoin et al., 2007).   Rhabdomyosarcoma is a rare 
childhood cancer that arises from undifferentiated muscle progenitor cells.  Current 
treatment can yield a disease-free survival rate of close to 67%, but the reason for the 
failure of the treatment for the remaining one-third of patients is largely misunderstood.  
Identification of biomarkers could help distinguish these patients from the responders to 
the traditional therapy, which would aid in pursuing better therapies, and possibly 
identify other novel potential drug targets.  The reverse phase microarrays were used as a 
platform to detect the phosphorylation status of proteins (using phospho-specific 
antibodies) thought to be distinguishing factors between the rhabdomyosarcoma 
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subtypes.  The group was able to identify higher phosphorylation levels in 4 Akt/mTOR 
pathway components that were only in patients with poor survival outcomes.  
Conversely, through bioinformatics analysis, they found that patients with good treatment 
outcomes exhibited mTOR pathway suppression.  Together, these findings suggest that 
pharmacologically suppressing the mTOR pathway could result in improved outcomes 
for patients who did not respond to the standard chemotherapy treatment.  Using a mouse 
xenograft model of rhabdomyosarcoma cell lines, there were able to test this hypothesis 
with known mTOR pathway inhibitors.  As expected, treatment with the inhibitor 
resulted in reduced phosphorylation of the protein 4E-BP1, a protein that had been 
identified in the array screen, as well as reduced tumor growth.  As a further proof of 
principle, they were able to demonstrate with the cell lysate arrays that specific patient 
sub-populations could be identified that benefited from personalized therapies and were 
able to identify the specific molecules that should be targeted in order to test these 
therapies.   
 Although this technique holds promise, there are several major problems with this 
approach.  First, well-characterized antibodies are not available for a great majority of 
human proteins, especially phosphoprotein-specific ones (Kalyuzhny, 2009; Couchman, 
2009).  Second, recent studies have advocated that many of the commercially available 
monoclonal antibodies may not even recognize their claimed targets, and can cross-react 
extensively with other cellular components (Jensen et al., 2009).  Third, when using 
antibodies for diagnostic and therapeutic applications, cross-reactivity is a large concern, 
as indicated by the recent withdrawal of several mAb-based pharmaceuticals from the 
market (Hughes, 2009; Berger et al., 2009).  Finally, this technique is not ideal for the 
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discovery of novel biomarkers, as prior knowledge and phospho-specific antibodies are 
required for any evaluation.   
 
Identification of Autoantibody Biomarkers for the Early Detection of Breast Cancer 
 
 While breast cancer awareness has resulted in many saved lives, current screening 
using mammograms detects only 70% of breast cancers, and false-positive mammograms 
leads to painful and unnecessary biopsies.  If one were to identify biomarkers allowing 
for early detection of breast cancer, it could provide a non-invasive and low cost method 
that also improves patient outcomes.  One arising category of cancer biomarkers is 
autoantibodies to tumor antigens.  They offer better stability, specificity, ease of 
purification and detection compared to other serum proteins.  Anderson et al treated 
NAPPA protein arrays (described previously) containing tumor antigens with either 
breast cancer patient or control serum samples, in order to identify any differences in the 
human antibody repertoire that could be used as a biomarker (Anderson et al., 2011).  
The first step in identifying new biomarkers used arrays containing 4,988 tumor antigens 
in order to eliminate uninformative autoantibodies that were present in both patient and 
control samples.  After identifying these background antigens, the number was reduced to 
761, which allowed them to fabricate much smaller arrays for the next phase of study that 
were cheaper and would contain less false positives.  In this next phase, sera from 
patients with invasive early breast cancer and benign breast disease were compared, 
resulting in 119 antigens that were present only in invasive cancer.  The third phase 
validated 28 antigens that maintained high levels of specificity in a blinded assay, one of 
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which was a known autoantigen ATP6AP1.  They were able to show high expression of 
ATP6AP1 in four breast cancer cell lines by western blot as well as higher ATP6AP1 
autoantibody levels in approximately 13% of early breast cancer serum samples 
compared to control.  While only a first step, this work demonstrates the usefulness of 
protein microarrays, particularly NAPPA arrays, in the identification of early biomarkers 
in breast cancer.   
 
Finding Autoantibody Biomarkers in Bladder Cancer 
 
 The utility of cancer biomarkers is in the development of new strategies for early 
diagnosis of disease, which allows for early intervention with current therapies and the 
improvement of patient survival rates.  Cancer-associated autoantibodies often target 
proteins that are mutated, modified, or aberrantly expressed in tumor cells, so they can be 
useful immunologic reporters that identify the molecular mechanisms underlying 
tumorigenesis.  This, in turn, may represent a good starting point for the development of 
new treatments.  With regards to bladder cancer, Orenes-Piñero and colleagues sought to 
identify not only autoantibody biomarkers of early bladder cancer, but also understand 
the underlying pathology of the disease (Orenes-Piñero et al., 2010).  Comparing serum 
samples collected from 12 patients with bladder cancer with 10 control patients using the 
Invitrogen Protoarray (an array consisting of ≈8,000 purified human proteins), they 
identified 171 differentially expressed proteins.   
Two proteins, clusterin and dynamin, were among the identified and were further 
validated using a custom tissue microarray comprised of bladder cancer tumor samples.  
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They applied immunohistochemistry to these arrays and found reduced expression levels 
of clusterin in muscle invasive bladder cancer, compared to non-muscle invasive tumors.  
It was also shown that low expression of dynamin was associated with increased tumor 
stage and grade, higher recurrence rate after surgery, and shorter survival.  Subsequent 
findings associating low levels of both clusterin and dynamin with disease appeared 
contradictory to the initial observation, which showed an increase in autoantibody levels 
to these proteins in patients with bladder cancer.  However, despite these contrary 
findings, they were able to demonstrate significant associations between clusterin and 
dynamin protein levels and disease progression, and still potentially make use of them as 
biomarkers in the clinic and for drug screens.   
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Cancer Type Substrate Probe Type Findings Reference 




 254 serum protein 
antibodies 
Patient sera Protein profiles 
(including C-Met) 
Sanchez-Carbayo 
et al., 2006 
Breast 4,988 candidate tumor 
antigens 
Patient sera 119 serum 
autoantibodies 
Anderson et al., 
2011 





Tao et al., 2008 
 Cytokine antibody array MGF7/Her2-18 
cell line 
Cytokine signatures 








Hudelist et al., 
2004 




Bartling et al., 
2005 
Pancreatic 48 antibody array Patient sera Glycan-alterations 
of MUC1 and CEA 
Chen et al., 2007 
Prostate 184 antibody array Patient sera 5 differentially 
regulated targets 
Miller et al., 2003 
 107 antibody array Patient sera Several targets, 
including 
Trombospondin-1 
Shafer et al., 2007 
Rhabdomyo-
sarcoma 




status of 27 proteins 
Petricoin et al., 
2007 
Table 6. Summary of Cancer Studies Using Protein Microarrays 
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1.7 Data Analysis and Bioinformatics     
 
One common characteristic of all microarray experiments is the generation of 
large quantities of data.  In order to elucidate interactions, careful statistical analysis is 
often required.  This is most commonly performed by bioinformaticians, who work in 
close collaboration with laboratory scientists to make sense of the vast pools of data 
generated from a typical experiment.  The analysis of data generated from protein 
microarray studies can be divided into two stages, or levels.  First level analysis involves 
obtaining a reliable signal intensity value for each spot on a protein microarray for a 
particular assay.  Second level analysis is more advanced analysis built upon the profile 
of signal intensity values obtained from the first level analysis. 
 
First level analysis 
 
The analysis at this level includes data acquisition, data normalization, and 
identification of hits. The raw data directly acquired from protein microarrays contain 
noise, which arise from various sources, such as inconsistent printing, uneven distribution 
of the reaction mixtures, inconsistent washing conditions, and batch effects. In most 
cases, algorithms developed for DNA/oligo microarray analysis can be applied to protein 
microarray analysis (Smyth et al., 2003).  It is often the case that proteins in a local 
region of the microarray show higher signal intensity than the overall intensity of the 
entire array.  Since proteins are usually printed in a random order on a protein 
microarray, without regard for biological structure or function, it is not expected that such 
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an effect is biological. To correct for this noise, the most useful normalization is the local 
normalization algorithm (e.g., ProCAT; Zhu et al., 2006).  For each spot, the average 
intensity of a small set of proteins (e.g., a 3-by-3 grid with the spot of interest in the 
middle) surrounding the spot as the local background intensity is used. Next, the local 
background is subtracted from the intensity of the spot of interest to achieve local noise 
correction. This process is then repeated for all spots on a protein microarray.  
The next step is to identify positive hits for a particular assay. Because of the high 
cost associated with protein microarrays, replicates are often not employed, so a vigorous 
significance (e.g., P value) for each protein can generally not be calculated.  Rather, the 
overall intensity distribution of proteins on a protein microarray is calculated.  In many 
cases, the distribution can be fit by a normal distribution curve.  Proteins with intensity 
above a certain number of standard deviations (e.g. 3 SDs) are considered positive hits.  
In some situations, a set of negative control experiments can be performed, generating 
intensity profiles that can be used to estimate the false discovery rate. 
 
Second level analysis 
 
Various bioinformatics tools are utilized or developed for the second level 
analyses.  Using biomarker identification as an example, the main question asked 
involves how to classify the groups of clustered proteins in order to draw conclusions.  In 
other words, the computational problem is identifying an optimal set of proteins that can 
best separate the disease from the control samples. Normally, if one can identify elevated 
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autoantibodies in disease samples relative to the controls, the corresponding autoantigens 
(i.e., human proteins) can serve as biomarkers for the disease.  
There are two major steps of the classification: 1) selection of a set of proteins, 
and 2) evaluation of the performance of this combination of these proteins.  Simply using 
the most antigenic protein may not be meaningful because its specificity and sensitivity is 
often not sufficient for diagnosis.  In addition, a brutal force search for protein 
combinations is also not feasible.  Different machine learning algorithms can be used to 
select the best combinations.  Examples of such models include those based on 
multivariate logistic regression, mixtures of Gaussian distributions (Skates et al., 2004), 
decision trees, artificial neural networks (ANNs), support vector machines (SVMs), and 
various approaches to incorporate these models in some kind of ensembles to improve 
overall performance (Zhang et al., 2006; Zhang et al, 2010).  In addition, heuristic 
searching algorithms, such as sequential forward search and sequential forward floating 
search, can also be used to search for the best combination of features (i.e., proteins) 
(Sahiner et al, 2000). 
The performance will be assessed by sensitivity, specificity, and receiver-
operating characteristic (ROC).  To derive models that are robust and hence, more likely 
biologically based, and to alleviate the constraint of typical suboptimal sample sizes, 
statistical re-sampling methods, such as bootstrap, k-fold or leave-one-out cross-
validation and introduction of artificial perturbations, have been widely utilized.  These 
combined with known databases and gene ontology (GO) analysis, narrow down hits to 
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 Scaffolding proteins are defined as proteins that interact with at least two other 
proteins in a signaling pathway.  As such, they play a crucial role in the regulation of 
cellular signal transduction. Protein phosphorylation and dephosphorylation is an 
important means of regulation and protein function that occurs in both prokaryotic and 
eukaryotic organisms. The phosphorylation of a protein may result in a conformational 
change in its structure leading to its activation or deactivation, and thus sequential and 
recursive phosphorylation of proteins allows the transmission of extracellular signals to 
intracellular targets. One well-known example is the RAS-ERK pathway, in which a 
small G-protein RAS activates MAP3K RAF, which then phosphorylates and activates 
MAP2K MEK1 (MAPKK1). MEK1 then phosphorylates and activates MAPK ERK (Shaw 
et al., 2009). Biological systems contain a large number of phosphorylation-related 
signaling pathways and proteins in different pathways may overlap with each other. This 
extensive cross-talk leads to the question of specificity, and understanding how each 
pathway is distinctly regulated is of great importance to the biological community. We 
believe the answer may partially lie in the existence of scaffolding proteins.  
 Scaffolding proteins act as a sort of “molecular glue,” linking multiple 
components in a pathway to facilitate signal transduction, and as such play crucial roles 
in the regulation of signaling cascades. They can enhance signaling specificity by 
sequestering proteins, preventing cross-talk between proteins in different signaling 
pathways. They can also increase the signaling efficiency by increasing the local 
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concentration of each signaling component. Thus, the knowledge of scaffolding proteins 
can help improve our understanding of the regulation of cellular signal transduction 
(Levchenko et al, 2000).  
 
2.2 Prediction of Scaffolding Proteins in Signaling Cascades 
 
 For a given protein pair, we calculated the distances for all possible paths 
connecting them in the protein-protein interaction (PPI) network.  A distance of 1 
indicates that two proteins directly interact with each other, while a distance of 2 
indicates that they both interact with a third protein.  Among 1,103 protein pairs with 
known kinase-substrate relationships (KSRs), 24.9% of them have a distance of 2 in the 
PPI network.  In contrast, of the 6.4x10
7
 human protein pairs in the PPI network, only 
2.7% have a distance of 2 (Figure 2.1). This stark enrichment suggests that protein 
mediators may play an important role in kinase signaling cascades.  
 
Figure 2.1 KSI pairs are significantly enriched in PPI distance=2. 24.9% of KSI pairs have PPI distance of 2, while only 2.7% of PPI 







 In order to predict potential scaffolding proteins in phosphorylation signaling 
cascades, the PPI and KSR networks were superimposed (Figure 2.2).  This was based on 
the assumption that a scaffolding protein interacts with most components in a phosphor-
signaling pathway.  
 
Figure 2.2 Schematic diagram of procedure to predict scaffolding proteins and related pathways. The randomized PPI is produced 
from real PPI by randomly selecting two PPI pairs and change their partners. The list of all possible phosphorylation pathways are 
produced by DFS searching algorithm. See method for details. 
 
 Here, the pathway is defined as a set of proteins with linear KSRs. For example, if 
protein A phosphorylates protein B, and protein B phosphorylates protein C, we 
constructed a pathway of A  B  C.  Continuous sub-paths within a long pathway will 
also be considered as separate pathways (such as A  B and B  C). Note that such 
defined pathways are not necessary to be the same biological pathway as those defined in 
other databases (eg. KEGG database).  
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 A very stringent requirement was made in predicting potential scaffolding 
proteins by examining whether any protein interacts with all components in a given 
pathway. Proteins with many known PPIs (eg. hub proteins) have a high chance of being 
scaffolding proteins.  In addition, short pathways tend to share common PPI partners.  To 
correct for these bias, simulations were performed to estimate the statistical significance 
for the prediction of scaffolding proteins. Random PPI networks were generated by 
permuting the PPIs, while keeping the interaction degree (i.e. number of interacting 
partners) for each protein.  In the random PPI networks, we calculated the chance that a 
protein predicted as a scaffolding protein for a pathway with the interaction degree of the 
protein and the length of the pathway as variables.  
 Choosing 0.01 as a False Discovery Rate cutoff, 212 proteins were predicted as 
scaffolding proteins, which target to 612 non-redundant phosphorylation pathways.  
Among the 1,103 known KSRs, 359 of them (33%) are associated with at least one 
predicted scaffolding protein. The resulting network is shown in Figure 2.3. 
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Figure 2.3. Network of predicted PSPs and proteins in their associated pathways. Scaffolding proteins were colored as red and 
proteins in pathways were colored as green. Scaffolding proteins were colored as blue if they were also proteins in pathways. Edge 
arrows were from scaffolding proteins to proteins in its related pathways. The size of node is proportional to its degree in network. 
 
 We then examined whether these scaffolding proteins are simply due to the high 
interaction degrees (numbers of interacting neighbors in the PPI network). Based on the 
PPI degree distribution, we found that the peak of the distribution locates around 10; on 
average, each scaffolding protein interacts with 10 proteins in PPI networks (Figure 2.4 
A). This distribution is similar to that of known scaffolding proteins (not shown). This 
result indicates the prediction of scaffolding proteins is unlikely to be an artifact due to 
their high PPI degrees, whereas, we did observed that proteins with high PPI degrees 




Figure 2.4 Statistics of predicted scaffolding proteins (PSPs). As a comparison, the distribution of background (all human proteins) 
was also drawn. (A) Distribution of PPI degree. (B) Distribution of protein length. (C) Distribution of protein conservation. The 
conservation was computed from the comparison with mouse proteome by BlastP. (D) Distribution of MS Phospho site numbers.  
 
 We observed that the occurrences of the scaffolding network motifs (i.e. one 
protein interacting with all components in a pathway) are significantly enriched 
compared to their occurrences in the networks where the PPIs were randomly permutated. 
For example, the scaffolding network motif with a phosphorylation cascade length of 6 
occurs 18 times, whereas we expect in only 0.26 times in a randomized network. This 
suggests that a scaffolding mediator is a widely-used mechanism in kinase signaling 
cascades.  
 We collected 78 possible scaffolding proteins for kinase signaling pathways 
through literature curation. Our prediction recovered 18 of them, which is more than a 3-
fold enrichment (p<1x10
-5
, hypergeometric distribution).  
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Of the 612 scaffolding mediated phosphorylation pathways, 414 (68%) are 
associated with only one scaffolding protein, suggesting that pathways are often 
specifically regulated by only one scaffolding protein (Figure 2.5 A). Instead, 61% of 
scaffolding proteins are associated with more than one pathway, suggesting that 
scaffolding proteins can participate in multiple pathways (Figure 2.5 B). 
 
Figure 2.5. Specificity of PSPs and pathways. (A) Number of PSPs related to paths. 31.3% of PSPs relates to only one path, but there 
are 37 PSPs related to no less than 20 paths. (B) Number of pathways related to PSPs. 3229 paths (83.9%) related to only one PSP. 
 
 Some partially overlapped pathways are involved in different biological processes 
and can be regulated by different scaffolding proteins.  For example, the MAPK signaling 
pathway RAF1  MAP2K1  MAPK1 is regulated by the scaffolding protein KSR2. The 
MAPK pathway is partially overlapped with the T-cell receptor signaling pathway, SRC 
 RAF1  MAP2K1, which is regulated by scaffolding protein MAPK8IP3. This 
example demonstrates that scaffolding proteins can provide specificity to the signaling 






2.3 Characterization of Scaffolding Proteins 
 
 We first examined the gene ontology (GO) annotation associated with the 
predicted scaffolding proteins. The GO biological process analysis indicates that 106 of 
the 212 predicted scaffolding proteins are associated with the GO term “signal 
transduction” (p<1x10
-28
, hypergeometric distribution), and 75 of them are annotated to 
be related to “intracellular signaling cascade” (p<1x10
-32
, hypergeometric distribution), 
both over three times enriched than expected (Figure 2.6). Furthermore, 38 of predicted 
scaffolding proteins are associated with the GO term “regulation of phosphorylation,” 
and 36 with “protein kinase cascade.” Although our prediction did not use these GO 
terms as an input, the GO analysis of the potential scaffolding proteins suggests the 
validity of our prediction.  
 




































 To characterize the predicted scaffolding proteins, we also examined the protein 
domains in these proteins as defined in Pfam. Compared to the expected occurrence of 
the corresponding domains, we found the predicted scaffolding proteins are enriched for 
several protein domains (Figure 2.6). Many enriched domains are known to interact with 
phosphorylation sites and play a role in signaling cascades, including SH2, SH3, 14-3-3, 
PH and Ank. Interestingly, kinase domains are also enriched, such as Pkinase and 
Pkinase_Tyr, suggesting that some scaffolding proteins are kinases themselves. As a side 
note, the two scaffolds used in this work (PIN1 and ATF2) did not have kinase domains 
enriched. Also of note, scaffolding proteins are generally large proteins because they 
need to interact with different proteins. The comparison between predicted scaffolding 
proteins and the human proteome shows the predicted scaffolding proteins are 
significantly larger than that of background (average 600 residues for scaffolding proteins 
vs. 200 residues for all human proteins) (Figure 2.4 B). However, some known and 
predicted PSPs are small proteins indeed, as they can form large complexes of polymer, 
such as ISCU (Chandramouli et al, 2007).  
 If scaffolding proteins are essential for signaling pathways, we expect that these 
proteins are under evolutionary constraint as well. By comparing with mouse protein 
sequences, we calculated the conservation score for each protein in humans. The 
predicted scaffolding proteins have an average conservation score of 0.90, while the 
average conservation score for all human proteins is 0.68 (Figure 2.4 C). In fact, 92% of 
predicted scaffolding proteins have conservation scores larger than 0.8, while on average 
we only expect that 47% of human proteins have that level of conservation.  
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 In an attempt to understand the interaction mode between scaffolding proteins and 
the pathways they mediate, we studied the phosphorylation sites on the predicted 
scaffolding proteins. We collected 31,000 known phosphorylation sites obtained from 
mass spectrometry experiments and then mapped these sites on the proteins. We found a 
majority of predicted scaffolding proteins (98%) contain at least one known 
phosphorylation site. In contrast, only 42% of proteins in the entire human proteome 
contain known phosphorylation sites (Figure 2.4 D). The high enrichment in phopho-
proteins implies that the interactions between scaffolding proteins and proteins in 
signaling cascades might be phosphorylation dependent.  
 
2.4 Validation of Scaffolding Proteins Using Protein Microarrays Shows ATF2 and PIN1 
Mediated Phosphorylation 
 
 In order to validate the predicted scaffolding proteins, kinase assays were carried 
out on the human proteome array, which contains over 17,000 full-length human proteins  
(Jeong et al., 2012).  Predicted scaffolding proteins were selected based on the ability to 
purify kinases with good activity, and contained kinase pathways that were easily 
inducible/inhibited for future in vivo validations (Table 2.1).  
 
Table 2.1 Validation hit list of predicted scaffolding proteins. *Known scaffolding protein. 
Kinases and scaffolds were purified from yeast as GST-fusion proteins and shown 
to have high quality by coomassie staining (Figure 2.7). Dot blot assays were performed 







to assess kinase activity using a mix of commonly phosphorylated proteins as a substrate 
(Histone H2, Histone H3, Casein, and MBP) in the presence of 
32
P-γ-ATP. Reactions 
were carried out for 30 minutes at 30°C before spotting onto nitrocellulose. Commercial 
PKA (1U/μL) was used as a positive control and negative control contained no enzyme. 
After drying, the nitrocellulose was washed 3 times with PBS and dried again. The 
membrane was exposed overnight to film before developing. All three kinases showed 
what we consider to be very good activity. Arrays were treated in duplicate with kinases 
with and without scaffold in the presence of 
33
P-γ-ATP for 30 minutes at 30°C in a 
humidity chamber. After incubation, the arrays were quickly immersed in two 400 mL 
beakers filled with TBST before washing 3 times with TBST for 10 minutes followed by 
3 washes with 0.5% SDS for 10 minutes. Arrays were quickly immersed in preheated 
37°C ddH2O before being spun dry by centrifugation (2 minutes at 2000 rpm). 
Microarrays were placed in a cassette and exposed to film for 30 days at -80°C.  
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Figure 2.7 Coomassie stain of scaffolding proteins and kinases shows high quality of purification. Dot blot using generic substrate 
mix indicates that kinases are very active against generic substrates.   
After 30 days, the film was developed and scanned before careful analysis using 
GenePix software.  To qualify as a true hit, stringent criteria were employed. Each array 
was carefully aligned and each hit was identified manually by eye. True hits had a F/B 
ratio greater than 1.5, were present in both replicates, and not present in the control 
arrays. After this analysis, 28 unique hits were discovered for the CSNK2A1 and MAPK9 
experiments (Table 2.2). To validate these hits, each spot was manually examined by eye 
and shown to be consistent with our conclusions (Figure 2.8). All in all, this marks a 
promising start in identifying scaffold-mediated protein phosphorylation and further in 
vivo studies will determine the scope of our observations. 
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Table 2.2 List of PIN1 and ATF2 meditated phosphorylation events. Each array was manually aligned and scored Final hits that were 
identified were replicated, not present in control arrays, and had F/B ratios >1.5. Proteins in bold were hit with both ATF2 and PIN1. 
   
 





 Signal transduction by phosphorylation is the most universal and well-studied 
mechanism that cells employ to mediate cell signaling, although there are still many 
interactions to discover. Kinase substrates have long been identified from their consensus 
sequence motifs, an amino acid sequence uniquely recognized by a particular kinase in 
which phosphorylation occurs. However, with the accumulation of experimental data, 
many kinases break this long-held rule and have been found to share similar 
phosphorylation motifs with other kinases, but identify totally different sets of substrates. 
This phenomenon has plagued many paradigms and can only be partially explained by 
differences in sub-cellular localization of kinase and substrate. Another recent 
explanation is in the form of protein docking and scaffolding proteins. Docking has 
frequently been used to indicate the binding of small molecule drug candidates to their 
protein targets, but can also be employed to indicate the weak and transient interactions 
between proteins (Halperin et al, 2002). Recent publications indicate that docking plays 
an essential role in the recognition of the substrate by a kinase. For example, GSK3 
kinase-catalyzed protein phosphorylation often requires a stable kinase-substrate docking 
interaction, and kinase BIN2 directly interacts with a 12 amino acid motif adjacent to the 
C-terminus of its substrate BZR1 in order to recognize it (Peng et al, 2010). Currently 
only a few docking motifs are known for kinases, but accumulation of these kinase 
docking motifs are critical in developing accurate prediction methods.  
 This work is a first trial attempt at large-scale projections of predicted scaffolding 
proteins (PSPs). We have developed a method to predict 212 PSPs we believe are of high 
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confidence. Relative to other proteins, PSPs are generally larger and have conserved 
protein sequences. They also contain more phosphorylation sites, indicating their 
scaffolding function may be phosphorylation dependent. Although proteins with high PPI 
degrees are more likely to be PSPs, not all proteins with high PPI degrees are predicted as 
such, indicating the predictions are less likely to be random. Initial microarray validations 
have provided a first start in validating this method. Twenty-eight substrates were found 
to be phosphorylated only in the presence of a predicted scaffold. Further studies will be 
necessary to further characterize these initial observations. The predicted PSPs are 
dependent on the ever expanding KSI and PPI databases, which, as they continue to 
accumulate more data, will be able to predict more PSPs in the future.  
 
2.6 Materials and Methods 
 
Protein-protein Interactions 
Human protein-protein interaction (PPI) data was collected from three databases: 
IntAct (ftp://ftp.ebi.ac.uk/pub/databases/intact/current/), HPRD 
(HPRD_Release_7_09012007, http://www.hprd.org/sentDataRequest) and BioGRID 
(biogrid-all-2.0.45.tab, http://www.thebiogrid.org/downloads.php). These data were then 






Computation of PPI Distance 
The PPI distances of a protein pair is defined as the shortest distance of the 
protein pair in the PPI network, and can be computed using Breadth-First Search (BFS) 
algorithm. We took each protein with PPI information as a root, and defined it as the first 
level of a tree. We then extended the root to take all its neighbors as the nodes at the 
second level of the tree. We next collected and took the neighbors of all nodes at second 
level as the nodes at the third level of the tree, and all nodes that had appeared in previous 
levels would be deleted. We repeated this procedure till no further level could be added to 
the tree. This resulted in the PPI distances between root node and all other nodes in the 
tree being the difference of their levels. For example, the PPI distance between root node 
(first level) and a node at the fourth level is 3. This allowed us to obtain the minimal 
distance of each protein pair. 
 
Identification of Phosphorylation-related PSPs 
We took each kinase as root, and extended its substrates one by one by a Depth-
First Search (DFS) algorithm. Each path starting from the root in the tree represents a 
possible phosphorylation pathway or its continuous substring. Here, we require the path 
must start from a root node, but does not need to end at leaf node. The minimum length 
of a pathway was set as 2. By doing it this way, we can list all possible phosphorylation 
pathways and their continuous substrings and remove any redundancies. We also 
included the continuous substrings of long pathways because they may not have 
corresponding PSPs, while its continuous substrings do. 
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Protein Microarray Assay 
 Proteins were purified, printed, and analyzed as described previously (Jeong et al, 
2012). Kinases and scaffolds ORFs were expressed as GST-fusion proteins in yeast. 
Cultures (50 mL) were grown at 30° C to OD600 1.0-1.2 and induced with 2% galactose 
for 4-6 hours. Harvested cells were lysed with glass beads in lysis buffer (100 mM Tris-
HCl [pH 7.4], 100 mM NaCl, 1 mM EGTA, 0.1% 2-mercaptoethanol, 0.5 mM PMSF, 
0.1% Triton X-100, protease inhibitor cocktail [Roche], and phosphatase inhibitor 
cocktails 2 and 3 [Sigma]). GST-proteins were bound to glutathione beads (GE 
healthcare) for 40 minutes at 4° C and washed 3 times with Wash Buffer I (50 mM Tris-
HCl [pH 7.4], 500 mM NaCl, 1 mM EGTA, 10% glycerol, 0.1% Triton X-100, 0.1% 2-
mercaptoethanol, and 0.5 mM PMSF) and 3 times with Wash Buffer II (50 mM HEPES 
[pH 7.4], 100 mM NaCl, 1 mM EGTA, 10% glycerol, 0.1% 2-mercaptoethanol, and 0.5 
mM PMSF) before 2 30 minute elutions in elution buffer (100 mM Tris-HCl [pH 8.0], 
100 mM NaCl, 10 mM MgCl2, 30 mM glutathione, and 20% glycerol). Eluate was 
collected and concentrations were determined through BSA standard.  
 Protein chips were briefly dipped in TBS to remove excess glycerol from printing 
procedure before blocking in 3 mL of blocking buffer (3% BSA in TBST) for 1 hour. 
Chips were washed 3 times in TBST before the addition of 125 uL of kinase buffer 
containing 3:1 scaffold:kinase in kinase buffer (50 mM Tris-HCl [pH 7.5], 100 mM 
NaCl, 10mM MgCl2, 1 mM MnCl2, 1 mM DTT, 1 mM EGTA, 25 mM HEPES-KOH 
[pH 7.5], 1 mM NaVO4, 1 mM NaF, 0.1% NP-40, 0.0000556 mM 
33
P-γ-ATP [Perkin 
Elmer; 2 μL/array]). Chips were placed in a humidity chamber and incubated for 30 
minutes at 30° C. Following the reaction, chips were quickly immersed in two separate 
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beakers of TBST and washed 3 times in TBST for 10 minutes followed by 3 washes in 
0.5% SDS for 10 minutes. Arrays were then quickly dunked in water heated to 37° C and 
dried by centrifugation before being arranged in a standard film cassette and exposed to 
film (Kodak BioMax MR) for 30 days. Cassette was stored at -80° C.  
 
Dot Blot Assay 
2 μL purified kinases were mixed with 1 μL substrate mix (1:1:1 casein:MBP:Histone H3 
100 ng/μL dissolved in TBS) and 2 μL 2.5x reaction buffer (90 mM Tris-HCl, pH 7.5, 
180 mM NaCl, 9 mM MgCl2, 0.9 mM MnCl2, 0.9 mM DTT, 9μM cold ATP, 2.5 mM 
EGTA, 20 mM HEPES-KOH, pH 7.5, 0.9 mM NaF, 0.9 mM Na3VO4, and 5.954E-05 
mM 
32
P-γ-ATP [Perkin Elmer; 0.2 μL/5.6 μL reaction mix]) and incubated at 30° C for 
30 minutes. Reactions were quenched by spotting entire mix onto nitrocellulose paper 
and drying for 15 minutes. Membrane was then washed 3 times for 10 minutes with PBS 
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Chapter 3: Profiling the O-GlcNAcylation of the Kinome Using Protein Microarray 
Technology 
3.1 Introduction 
Signal transduction in cells largely relies on the large, dynamic mix of inducible 
post-translational modifications (PTMs) of proteins. Whether phosphorylation, 
ubiquitylation, acetylation, or nitrosylation, the list of modifications and substrates tied to 
them continues to grow. While phosphorylation has certainly been the most well-studied 
PTM, especially as it relates to serine and threonine modification, recently proteins 
modified by β-N-acetylglucosamine (O-GlcNAc) have been emerging as prominent 
players in regulating cell signaling, cell division, transcription, and metabolism (Hart et 
al., 2007; Zeidan et al., 2010). The cycling of O-GlcNAc on proteins is facilitated by two 
enzymes, O-GlcNAc transferase (OGT), which catalyzes the addition of O-GlcNAc, and 
O-GlcNAcase (OGA), which removes O-GlcNAc through hydrolysis. The dynamics 
between these two enzymes is regulated through various stimuli, and the myriad of 
proteins that have been detected with this modification is just as varied. Transcription 
factors, histones, cytoskeletal proteins, and some kinases have all been identified as being 
O-GlcNAcylated (Hart et al., 2011). The effect of O-GlcNAcylation on proteins is varied 
as well. One of the more well-characterized examples is the modulation of 
calcium/calmodulin-dependent kinase IV (CaMKIV) activity by it’s O-GlcNAcylation 
(Dias et al., 2009; Song et al., 2008; Slawson et al., 2010). In its basal/inactive state, 
CaMKIV is heavily glycosylated. Upon stimulation and calcium influx, S189 O-
GlcNAcylation is removed by OGA, exposing the active loop site, allowing CaMKK to 
phosphorylate CaMKIV at S200 and activate it. Oftentimes, O-GlcNAcylation sites are 
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also phosphorylation sites, as is the case with nitric-oxide synthase (Du et al., 2001), c-
Myc (Kamemura et al., 2002), and RNA polymerase II (Comer et al., 2001). However, 
this reciprocal relationship is not always seen. Several proteins can be both O-
GlcNAcylated and phosphorylated at distant sites, or modification on adjacent sites can 
alter the modification of the other (Yang et al., 2006).  
Recently, studies have altered the assumption that O-GlcNAc and 
phosphorylation are simply antagonistic toward each other by exhibiting that while 
increasing global O-GlcNAcylation did indeed decrease a large number of 
phosphorylation events, it also increased phosphorylation at many other sites (Wang et 
al., 2008). This implies that although O-GlcNAcylation may compete with kinases for 
site modification, it may also modify kinases and phosphatases as well. This leads to a 
great void in understanding how OGT/OGA and kinases/phosphatases are regulated and a 
high throughput approach to identify kinase substrates of OGT would be very useful in 
understanding the reach of O-GlcNAcylation on the kinome. Initial studies in the Hart lab 
used [H
3
] radiolabeling on a small functional microarray identified 42 kinases as being 
O-GlcNAcylated (Dias et al., 2012). However, the severe sensitivity limitations of the 
assay left something to be desired. This led to a collaboration between the Zhu and Hart 
labs and the development of a three-pronged approach to probe the kinome using protein 





3.2 Kinome Collection, Purification and Microarray Fabrication 
 
In order to study the O-GlcNAcylation of kinases, a kinome collection was 
consolidated from the Invitrogen ORF collection. After Pfam analysis to eliminate any 
clones that did not possess a canonical kinase domain, a final list was obtained that 
contained 350 unique kinases, representing about 70% of the human kinome (Table 3.1). 
The collection contains kinases from almost all kinase families, including AGC, CAMK, 
CK1, CMGC, STE, TK, and TKL. Each kinase was expressed in yeast as a GST-fusion 
protein and affinity purified using glutathione sepharose beads (GE Healthcare). Protein 
purity and amounts were assessed using Coomassie staining against BSA standards 
(Figure 3.1).  
Clone ID Gene Symbol Clone ID Gene Symbol Clone ID Gene Symbol Clone ID Gene Symbol Clone ID Gene Symbol 
IOH5262 AAK1 IOH11766 CSNK1A1L IOH29960 MAP2K1 IOH26671 PAK1 IOH36120 RPS6KA6 
IOH40442 ABL2 IOH4975 CSNK1D IOH3639 MAP2K2 IOH2475 PAK4 IOH29907 RPS6KB1 
IOH21860 ACVR1 IOH21160 CSNK1E IOH21715 MAP2K3 IOH6311 PAK4 IOH29003 RPS6KB1 
IOH4418 ACVR1B IOH21026 CSNK1G1 IOH29276 MAP2K4 IOH21457 PAK4 IOH6536 RPS6KB2 
IOH10813 ACVR1C IOH10417 CSNK1G2 IOH28657 MAP2K4 IOH20961 PAK6 IOH4738 RPS6KB2 
IOH29719 ACVR2A IOH27760 CSNK1G2 IOH6702 MAP2K5 IOH12390 PBK IOH6324 RPS6KL1 
IOH63235 ACVR2B IOH26429 CSNK1G3 IOH59078 MAP2K6 IOH6258 PCTK1 IOH63009 SCYL1 
IOH63228 ACVR2B IOH13704 CSNK2A1 IOH27169 MAP2K7 IOH4605 PCTK1 IOH61176 SCYL2 
IOH21048 ACVRL1 IOH6369 CSNK2A2 IOH9668 MAP3K11 IOH9712 PCTK3 IOH13493 SCYL3 
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IOH29100 ADCK1 IOH21981 DCAMKL2 IOH45191 MAP3K13 IOH27481 PCTK3 IOH3192 SGK 
IOH22636 ADCK5 IOH20970 DCLK1 IOH27594 MAP3K14 IOH22618 PDGFRB IOH14023 SGK2 
IOH25981 ADRBK1 IOH5763 DDR1 IOH21077 MAP3K7 IOH12032 PDIK1L IOH35747 SGK2 
IOH56275 ADRBK2 IOH28909 DDR2 IOH29760 MAP3K7 IOH10145 PDK3 IOH41642 SGK3 
IOH3692 AKT1 IOH40696 DMPK IOH37873 MAP3K7 IOH25726 PDK4 IOH29894 SNF1LK 
n/a AKT2 IOH14793 DYRK1B IOH29592 MAP3K8 IOH14589 PDPK1 IOH45349 SNF1LK2 
IOH43070 AKT3 IOH2412 DYRK2 IOH26933 MAP4K2 IOH27406 PDPK1 IOH61637 SNRK 
IOH37801 AKT3 IOH6475 DYRK2 IOH45342 MAP4K2 IOH37739 PFTK1 IOH12563 SRC 
IOH7002 ALS2CR2 IOH61505 DYRK3 IOH27202 MAP4K5 IOH4032 PHKG2 IOH26832 SRPK1 
IOH25914 ALS2CR7 IOH21591 DYRK4 IOH12327 MAPK1 IOH21022 PIK3C3 IOH26788 SRPK2 
IOH6107 ARAF IOH21995 EEF2K IOH29657 MAPK10 IOH11272 PIM2 IOH38187 SRPK2 
IOH21137 ARAF IOH5879 EIF2AK1 IOH46259 MAPK10 IOH39671 PIM3 IOH21169 STK11 
IOH27785 AURKB IOH29605 EIF2AK2 IOH11420 MAPK11 IOH11596 PINK1 IOH4116 STK16 
IOH60102 AURKC IOH45194 EPHA3 IOH21127 MAPK12 IOH21301 PKMYT1 IOH28976 STK16 
IOH22600 AXL IOH39415 EPHB1 IOH3435 MAPK13 IOH26045 PKN1 IOH56487 STK17A 
IOH57009 BLK IOH28858 EPHB3 IOH4647 MAPK14 IOH40845 PKN3 IOH27608 STK24 
IOH27203 BMP2K IOH29406 EPHB4 IOH45415 MAPK15 IOH5070 PLK1 IOH62982 STK24 
IOH22419 BMPR1A IOH60258 ETNK1 IOH12559 MAPK3 IOH57150 PLK2 IOH27916 STK25 
IOH26729 BMPR1B IOH12251 ETNK2 IOH29678 MAPK6 IOH14035 PLK3 IOH6735 STK25 
IOH44883 BMPR2 IOH12546 FASTK IOH25729 MAPK6 IOH21855 PNCK IOH9738 STK3 
IOH11645 BMX IOH25748 FGFR1 IOH5845 MAPK7 IOH12321 PRKAA1 IOH29261 STK31 
IOH45178 BRD2 IOH21425 FGFR1 IOH13115 MAPK7 IOH27141 PRKAA1 IOH12468 STK32A 
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IOH14775 BRSK2 IOH36731 FGFR2 IOH29959 MAPK8 IOH26755 PRKAA1 IOH26023 STK32B 
IOH39717 BTK IOH36732 FGFR2 IOH53990 MAPK8 IOH29876 PRKAA2 IOH27515 STK33 
IOH21042 BUB1 IOH27231 FGFR2 IOH21974 MAPK9 IOH26286 PRKACA IOH11118 STK36 
IOH45542 C9orf96 IOH13371 FGFR4 IOH42152 MAPK9 IOH10103 PRKACB IOH13030 STK38 
IOH26033 CAMK1D IOH21152 FGR IOH3889 MAPKAPK3 IOH27691 PRKACB IOH11742 STK38L 
IOH26807 CAMK2A IOH42245 FLJ23356 IOH28010 MAPKAPK5 IOH45130 PRKACG IOH7196 STK4 
IOH45432 CAMK2B IOH60533 FLJ25006 IOH63098 MARK2 IOH29644 PRKCA IOH6969 STK40 
IOH46514 CAMK2D IOH62170 FLJ25006 IOH10665 MARK3 IOH43969 PRKCB1 IOH40615 STK40 
IOH22233 CAMK2G IOH56137 FRK IOH29899 MAST1 IOH22061 PRKCB1 IOH29558 STYK1 
IOH22804 CAMKK1 IOH21081 FYN IOH46175 MAST2 IOH26352 PRKCD IOH4914 SYK 
IOH26370 CAMKK1 IOH21890 FYN IOH4506 MATK IOH26823 PRKCH IOH9759 SYK 
IOH45150 CAMKK2 IOH3380 GAPDH IOH45826 MATK IOH56035 PRKCI IOH21006 TBK1 
IOH37934 CAMKK2 IOH22295 GAPDH (sperm) IOH36570 MET IOH42544 PRKCQ IOH26839 TBK1 
IOH12294 CAMKK2 IOH45159 GRK5 IOH46178 MGC16169 IOH5838 PRKCZ IOH23271 TESK2 
IOH21132 CAMKV IOH14078 GRK6 IOH27623 MGC42105 IOH38433 PRKD2 IOH14312 TNK2 
IOH27787 CAMKV IOH62403 GSG2 IOH5352 MKNK1 IOH40726 PRKG1 IOH62118 TNNI3K 
IOH14583 CDC2 IOH11473 GSK3A IOH37765 MKNK2 IOH45425 PRKX IOH21149 TRIB2 
IOH45143 CDC2L1 IOH4507 GSK3B IOH53775 MKNK2 IOH59135 PRKY IOH14340 TRIB3 
IOH3095 CDC2L5 IOH14630 HCK IOH21529 MLKL IOH45196 PRPF4B IOH27427 TRIB3 
IOH39710 CDK10 IOH27205 HIPK1 IOH35579 MOS IOH27426 PTK2 IOH27746 TSSK2 
IOH41508 CDK10 IOH22334 HIPK1 IOH44055 MYLK IOH28634 PTK2B IOH27376 TSSK3 
IOH29645 CDK3 IOH22267 HIPK4 IOH45160 MYLK2 IOH37738 PTK6 IOH27738 TTBK2 
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IOH12184 CDK4 IOH5257 HSPB8 IOH26905 MYO3A IOH14307 PXK IOH4197 TTK 
IOH5192 CDK4 IOH38087 ICK IOH26432 NEK10 IOH28936 RAGE IOH21117 TYK2 
IOH4873 CDK5 IOH36576 IGF1R IOH28791 NEK2 IOH5435 RET IOH26747 TYRO3 
IOH28111 CDK6 IOH6284 IKBKB IOH10648 NEK3 IOH9973 RFP IOH28850 TYRO3 
IOH3121 CDK7 IOH29703 ILK IOH45183 NEK4 IOH61477 RFP IOH14193 UHMK1 
IOH2136 CDK9 IOH12099 IRAK1 IOH14564 NEK6 IOH40612 RIOK1 IOH45122 ULK3 
IOH25876 CDKL3 IOH29139 IRAK3 IOH45126 NEK7 IOH6368 RIPK2 IOH10843 ULK4 
IOH27246 CDKL5 IOH54085 ITK IOH45357 NEK8 IOH26143 RIPK3 IOH41408 VRK1 
IOH5501 CERK IOH29900 JAK2 IOH62004 NEK9 IOH62447 RIPK5 IOH11957 VRK2 
IOH21007 CLK1 IOH61636 KIT IOH53723 NLK IOH62446 RIPK5 IOH27845 VRK3 
IOH28987 CLK2 IOH34863 KSR2 IOH63245 NPR2 IOH39650 RP6-213H19.1 IOH27052 WEE1 
IOH14562 CLK2 IOH45203 LATS1 IOH4821 NRBP1 IOH12130 RPS6KA1 IOH23113 WNK1 
IOH6643 CLK3 IOH11874 LCK IOH29759 NRBP2 IOH3648 RPS6KA2 IOH26758 YES1 
IOH4008 CLK3 IOH28609 LYK5 IOH54159 NTRK3 IOH63248 RPS6KA3 IOH22867 YSK4 
IOH54018 CLK4 IOH45129 LYK5 IOH36839 NUAK1 IOH29892 RPS6KA4 IOH27465 ZAP70 
IOH29870 CSK IOH39743 LYN IOH21129 NUAK2 IOH45179 RPS6KA5 IOH28978 ZAP70 
IOH59150 CSNK1A1 IOH26189 MAK IOH21155 OXSR1 IOH45431 RPS6KA5 IOH45475 ZAP70 
Table 3.1 The 350 unique kinases on the Kinome microarray. Each distinct IOH number represents a unique protein. More 






Figure 3.1 Representative coomassie stain for purified GST-tagged kinases (SimplyBlue stain, Life Technologies)  
 
    
1. TTK Elution 1 











Figure 3.2 The kinome array. High microarray printing quality is shown using anti-GST primary 
antibody (mouse, Sigma) and goat anti-mouse Cy3 secondary antibody (Life Technologies)   
1     2     3     4    5     6     7     8     9   10   11   12       250  500 750 1000 
BSA (ng) 
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Following purification, the kinases were re-arrayed into 384-well plates before 
contact printing with a BIO-RAD VersArray ChipWriter Pro System. Each kinase was 
printed in duplicate as part of a large 16x48 grid that included the 350 kinases as well as a 
series of controls (including histones, BSA standards, and serial dilutions of GST). Each 
microarray contained two of these large grids for a total of four replicates of each kinase. 
Printing quality was assessed using an anti-GST primary antibody and a Cy3-labeled 
secondary antibody (Figure 3.2). Microarrays used in the antibody-based detection of O-
linked glycosylation were printed on Full Moon slides (FullMoon Biosystems), while 
those used in the click chemistry detection were printed on epoxide slides (SuperEpoxy 2, 
Arrayit Corporation).  
 
3.3 In vitro Glycosylation Reaction 
 
In order to assess the breadth of kinome glycosylation, we developed protocols 
for three different methods of detecting the O-GlcNAcylation of the kinome. The first 
two approaches use antibodies that specifically bind to O-glycosylated proteins (RL2 and 
CTD110.6), while the third approach uses click chemistry to specifically label O-
glycosylated proteins (Figure 3.3). 
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Figure 3.3 General schematic for microarray experiments. Arrays were both labeled with OGT followed by detection with either click 
chemistry or antibody-based approaches. 
 
The general antibody-based assay involves blocking with 3% BSA in TBST for 1 
hour at room temperature with gentle shaking followed by 3 10 minute washes in TBST. 
Arrays were then treated with ncOGT or enzyme buffer (as negative control) in the 
presence of UDP-GlcNAc for 2 hours at room temperature under a coverslip and in a 
humidity chamber. Following OGT labeling, arrays were washed 3 times in TBST (after 
initial immersion in 400 mL TBST to remove coverslips) for ten minutes before 
incubation with Cy5-labeled antibody. A final concentration of 20ng/μL was used for 
RL2 and 5 ng/μL for CTD110.6. Arrays were exposed to each antibody for 2 hours at 
room temperature under a coverslip and in a humidity chamber. Arrays were quickly 
immersed in 400 mL TBST and washed 3 times in TBST for ten minutes. Following the 
final wash, arrays were quickly immersed in preheated 37° ddH2O and placed in a drying 
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rack, where they were spun dry by centrifugation (2 minutes at 2000 rpm). Arrays were 
then scanned with a GenePix 4000 scanner (MDS Analytical Technologies) before 
careful alignment using GenePix software. 
The click chemistry approach used arrays that were printed on epoxide slides 
(SuperEpoxy 2, Arrayit Corporation). Pilot studies for this approach using FullMoon 
slides showed tremendous amount of background that was abolished when using the 
epoxide slides. Arrays were also blocked with SuperBlock (Thermo Scientific) for 1 hour 
at room temperature. After blocking, arrays were washed and labeled with OGT as 
before. After labeling (and subsequent wash steps), arrays were further treated with the 
permissive mutant β-1,4-galactosyltransferase (GalT1 (Y289L)), which transfers azido-
modified galactose (GalNAz) from UDP-GalNAz to O-GlcNAc residues of modified 
proteins (Click-iT
TM
 O-GlcNAc Enzymatic Labeling System, Invitrogen). GalT1 
treatment was performed overnight at 4°C under a coverslip. The following morning, 
arrays were immersed in 400 mL of TBST to remove the coverslips and washed 3 times 
for 10 minutes in TBST. Contrary to the antibody approach, the arrays were washed 2 
times for 10 minutes with 0.5% SDS as well. This was done to eliminate some 
background signal that was seen in pilot studies when just performing TBST washes. 
Following the final wash, the arrays were treated with 1 μM Alexa Fluor® 647 DIBO 
alkyne for 2 hours at room temperature under a coverslip and in a humidity chamber. 
This copper-free labeling method had much less background than the traditional copper-
catalyzed method. After incubation, arrays were washed 3 times in TBST for 10 minutes 
before quick immersion in preheated 37° ddH2O and drying through centrifugation (2000 
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rpm for 2 minutes). As before, arrays were scanned with a GenePix 4000 scanner (MDS 
Analytical Technologies) before careful alignment using GenePix software.  
Representative images are shown in Figure 3.4 for all three detection methods.  
 
Figure 3.4 Representative images of three detection methods.  
 
In order to identify positive hits, we performed a background subtraction from 
each spot, averaging the values between replicate spots in the same large block first, and 
then averaging the values between the two large blocks to obtain an average F-B value 
for each kinase. The ratio was then determined between OGT treated and untreated arrays 





Figure 3.5 Data analysis schematic using RL2 antibody detection as an example. Background subtraction is averaged between 
replicates in large block as well as between blocks before ratio is determined between OGT treated and untreated samples. Each 
experiment was repeated twice for each detection method. Threshold was determined experimentally to be 2.0.  
 
As a proof of principle and validation that the antibodies were not non-
specifically binding to the array, we diluted each antibody in increasing amounts of free 
GlcNAc as competition to abolish any non-specific binding. As expected, signal for both 
RL2 and CTD110.6 decreased dramatically upon competition (Figure 3.6 A). Clostridium 
perfringens NagJ (CpNagJ) is a close homolog of human O-GlcNAcase, the enzyme that 
hydrolyzes O-linked glycosylation. CpNagJ has been shown to have high conservation in 
the active site with human OGA, and has been shown to have activity on human 
substrates (Rao et al., 2006). As another proof of principle, we treated the array with or 
without CpNagJ (and with or without OGT) and saw a dramatic loss in signal. We were 
then able to rescue some of the hits after CpNagJ treatment using OGT again on the array 
Average F-B (+ OGT) 






Average F-B (+ OGT) 
 
Average F-B (- OGT) 
> 2.0 
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(Figure 3.6 B). While we weren’t able to rescue all of the signal we had originally, we 
attribute that to the three consecutive reactions that were performed on the arrays (over 
the course of 9 hours and 12 washes) which likely led to protein unfolding and an 
inability of OGT to efficiently modify the proteins after CpNagJ treatment. However, the 
fact that we saw the expected results for both the competition assay and the CpNagJ 
treatment gives us great confidence in the hits that we initially generated using both RL2 
and CTD110.6.  
 
Figure 3.6 Establishing the specificity of RL2 and CTD110.6. (A) By using increasing concentrations of free GlcNAc, we see an 
abolishment of signal, signifying that the initial signal is a true measure of O-GlcNAcylation. (B) Treatment of the arrays with 
Clostridium perfringens NagJ (CpNagJ) results in a decrease in signal, signifying removal of O-GlcNAcylation. The signal is partially 
rescued upon further treatment with OGT.   
 
After establishing the general validity of our methods using competition and 
CpNagJ treatment, each detection method was repeated twice, with high reproducibility. 
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For RL2 detection, 328 of the 341 hits (96%) were shared between duplicate 
experiments. Similar results were seen for CTD110.6 (218/318; 69%) and click chemistry 
(183/339; 54%).  
3.4 In vitro Validations  
To begin establishing a threshold for our hit lists, we sought to validate a variety 
of hits in vitro. To that end, several kinases were selected that were in three different 
categories based on our microarray data; 1) Those that were hit by all three methods in 
duplicate at a starting threshold of 2.0 (i.e. 2-fold signal intensity above non-treated 
sample), 2) those that were hit 5 out of 6 times (i.e., were present in all duplicates for 
each method except for one), and 3) those that were not hit at this initial threshold (Table 
3.2). 
Hit by All 3 Methods Hit by 5 of 6 Methods Not Hit at 2.0 
CSNK1A1 BRSK2 PIM3 
ETNK2 SYK CAMKK1 v.1 
Src SRPK2 RIPK3 
MAPK8 CSNK2A1 PBK 
PAK4 EEF2K  
 TTK  
 MYO3A  
 STK33  
 HIPK1*  
Table 3.2 Hits selected for further validation studies. HIPK1 is a known positive control. 
 
In order to perform in vitro O-GlcNAcylation, each kinase was purified as a GST-
fusion protein in yeast as before and treated with and without OGT before western 
transfer. Membranes were either probed with RL2 or CTD110.6 antibody (1:2000 and 





Figure 3.7 First phase validation. (A) in vitro validations of GST-fusion kinases were classified three ways; 1) Hit by all methods, 2) 
Hit by 5 out of 6 replicates, and 3) not hit at 2.0 threshold. (B) Western validations with representative array image references.  
  
As shown in Figure 3.7 A, all four hits that were observed by all three methods 
were validated (CSNK1A1, ETNK2, Src, and PAK4) and 5 of 7 hits detected by 5 of the 6 
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replicates were validated as well (BRSK2, EEF2K, TTK, CSNK2A1, and HIPK1). 
Importantly, the two hits tested that did not show signal over thresholds were shown to be 
negative, as expected (PIM3 and PBK). The high success rate of the in vitro validations 
strengthens our confidence in our findings. 
 As another method of validation, we performed in vitro assays with CpNagJ on 6 
proteins (2 from each classification) (Figure 3.8). As expected, treatment with CpNagJ 
diminished signal and OGT treatment intensified signal among positive hits (ETNK2, 
MAPK8, MYO3A, and STK33). No signal was seen for both kinases that were not hits at 
our threshold of 2.0 (CAMKK1 v.1 and RIPK3). 
 
Figure 3.8 in vitro validations using CpNagJ to remove O-GlcNAcylation. GST-fusion proteins were treated with OGT and/or 
CpNagJ before western transfer and antibody probing. As expected, CpNagJ treatment diminished signal, while OGT intensified 
signal among positive hits. 
 
3.5 In vivo Validations of PAK4 and Other Substrates 
In order to further validate hits, kinases were shuttled into an N-terminal FLAG-
tagged mammalian expression vector (pSG5-FLAG, Agilent Technologies) and 
expressed in HeLa cells. 48 hours after transfection, cells were treated for 4 hours with 
the O-GlcNAcase inhibitor TMG to raise global levels of O-GlcNAcylation. Cells were 
then lysed and treated with anti-FLAG M2 agarose beads (Sigma) overnight at 4°C with 
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shaking. After washing, proteins were eluted with loading buffer, run on a gel, and 
transferred to nitrocellulose for western blotting. Blots were probed with both CTD110.6 
and anti-FLAG and 9 kinases were validated in vivo (Figure 3.9). 
 
Figure 3.9 in vivo validations in HeLa. FLAG-tagged substrates were expressed and 48 hours after transfection, cells were treated 
with TMG for 4 hours. Cells were lysed and affinity IP was performed using anti-FLAG M2 agarose beads before western transfer.  
  
3.6 Generation of High Confidence Hit List  
 
After successfully validating several kinases in vivo, we were confident in our initial 
assessment of a threshold of 2.0, especially since every kinase tested that was shared by 
all three methods was validated. Therefore, a final high confidence hit list was generated 
based on two stringent criteria; 1) each hit was present on both replicates using the same 
detection method and 2) each hit was present using all three detection methods (RL2, 
CTD110.6, and click chemistry) (Figure 3.10). This high confidence list contains 104 
kinases (Table 3.3).  
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Figure 3.10 Comparison of hits detected by all 3 methods. 104 hits were shared.   
Hits By All 3 Methods (RL2, CTD110.6, and Click Chemistry) 
ACVR1 DMPK MAPK1 PRKCD 
ACVR2B EIF2AK1 MAPK12 PRKD2 
ADRBK1 EIF2AK2 MAPK15 PTK6 
ADRBK2 EPHA2 MAPK6 RAGE 
AKT2 ETNK2 MAPK6 RFP 
AKT3 v.1 FASTK MAPKAPK5 RIPK5 
AKT3 v.2 FGR MARK3 RPS6KB1 
ARAF FLJ25006 MATK RPS6KB1 
AURKB GAPDH MET RPS6KL1 
AXL GSK3A MOS SCYL1 
BLK ICK NEK6 SGK2 
BMP2K IGF1R NEK7 SRC 
BMPR1A IRAK1 NLK STK16 
BMPR1B ITK NRBP2 STK16 
BMPR2 KSR2 PAK4 v.1 STK32B 
C9orf96 LATS1 PAK4 v.2 STK38 
CDK4 LRRK2_2 PCTK3 STK38L 
CDK5 LRRK2_3 PCTK3 STYK1 
CDK9 LYK5 PDIK1L SYK 
CDKL5 LYN PHKG2 TRIB3 
CSK MAP2K4 PINK1 TYK2 
CSNK1A1 MAP2K4 PKMYT1 ULK3 
CSNK1E MAP2K6 PLK4 VRK1 
DCLK1 MAP2K7 PRKAA2 VRK3 
DDR1 MAP3K7 PRKACG YES1 
DDR2 MAP4K5 PRKCB1 ZAP70 
Table 3.3 List of 104 kinases shared between 3 detection methods.  
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 In order to begin characterization of the kinases, we performed gene ontology 
analysis to see if any terms were enriched among our dataset. This was done using the 
online software Gene Ontology Enrichment Analysis Software Toolkit (GOEAST; Zheng 
et al., 2008). As expected, there weren’t many significant GO enrichments for a dataset 
consisting entirely of kinases. Almost all of the GO terms were related to generic kinase 
function (i.e. ATP binding, protein S/T kinase activity, enzyme binding, etc.). However, 
some interesting terms were seen that have been shown to be involved with OGT as well 
(Table 3.4). Given the fact that there is only one OGT gene in all advanced organisms, it 
is not surprising that there are a wide variety of processes that may be involved with 











process Response to stress 44 2.232 1.75E-17 
GO:0043408 
Biological 




Immune response-activating signal 
transduction 18 4.140 3.12E-15 
GO:0008219 
Biological 
process Cell death 23 2.917 4.57E-12 
GO:0006915 
Biological 




Cyclin-dependent protein kinase 
activity 7 6.261 6.40E-10 
GO:0016477 
Biological 
process Cell migration 17 3.105 1.68E-09 
GO:0045595 
Biological 
process Regulation of cell differentiation 21 2.513 9.98E-09 
GO:0007596 
Biological 
process Blood coagulation 12 3.396 1.89E-07 
GO:0042060 
Biological 
process Wound healing 13 3.047 6.62E-07 
GO:0045121 
Cellular 
component Membrane raft 9 3.783 2.08E-06 
GO:0032868 
Biological 
process Response to insulin stimulus 9 3.599 5.74E-06 
GO:0008283 
Biological 
process Cell proliferation 11 2.545 0.000210 
GO:0005815 
Cellular 
component Microtubule organizing center 9 2.599 0.001116 
Table 3.4 Gene ontology analysis from GOEAST. Most enrichment categories were related to general kinase function, but several 
interesting enrichments are seen. The larger the log odds ratio (base 2), the stronger the enrichment. P-values are calculated 
hypergeometrically to calculate enrichment.  
 
3.7 Identification and Confirmation of Glycosylation Sites Using Mass Spectrometry  
Next, we set to identify actual sites of O-GlcNAcylation for some of our kinase 
hits. To that end, BRSK2 and PAK4, which had both been validated in vitro and in vivo, 
were purified as GST-fusion proteins in yeast as before. They were then labeled and 
submitted for mass spectrometry. S691 of BRSK2 was identified as being glycosylated 
(Figure 3.11 A), while PAK4 showed 4 potential glycosylation sites (S12, S242, S243, 
and S267) (Figure 3.11 B).  
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Figure 3.11 Spectra from ETD mass spectrometry (A) S691 of BRSK2 identified and (B) S12 of PAK4 identified as O-
GlcNAcylated. S242, 243, and 267 of PAK4 were also identified (not shown). 
In order to validate these sites, we performed SA mutagenesis on PAK4 at each 
site individually, as well as a 4A mutant containing all four putative sites. Following 
mutagenesis, entry clones were shuttled into the pSG5-FLAG expression vector for 
expression in mammalian cells. As before, cells were transfected with PAK4 for 48 hours 
before 4 hours of TMG treatment. Cells were then lysed and immunoprecipitated with 
anti-FLAG M2 agarose beads overnight before washing and separation by gel 
electrophoresis. Proteins were then transferred to nitrocellulose for western blotting using 
both CTD110.6 (1:10,000) and α-FLAG (1:1000) antibodies. As seen in Figure 3.12, the 
S12A mutant exhibits an approximately 50% decrease in intensity compared to wild type, 
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and the 4A mutant (containing S12A, S242A, S243A, and S267A) shows >80% 
reduction. These results signify that the sites identified by mass spectrometry are of high 
quality. More importantly, it provides us with great confidence that the hits we obtained 
on our microarray have enough fidelity to be able to successfully identify individual sites 
of O-GlcNAcylation.  
 




O-linked N-acetylglucosamine (O-GlcNAc) was discovered in the early 1980’s 
when bovine milk galactosyltransferase (GalT1) was used to probe for terminal N-
acetylglucosamine moieties of glycoconjugates in living cells, yet it continues to be 
difficult to detect and quantify in many systems (Torres et al., 1984). Part of the reason 
for this is the fact that O-GlcNAcylation is generally undetected by standard analytical 
protein methods, such as gel electrophoresis and HPLC (Roquemore et al., 1994; Zachara 
et al., 2004). For one, O-GlcNAcylation generally does not result in gel shifts during 
electrophoresis, isoelectric focusing, or even 2D gels. Secondly, the sugar moieties can be 
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readily hydrolyzed by cellular hexoaminidases during cell damage or protein purification. 
Third, traditional mass spectrometry renders the O-GlcNAc modification very labile, and 
is traditionally lost (Wang et al., 2010). This, combined with the fact that O-GlcNAc-
peptide ion signals are generally suppressed even when modified peptides are in the 
majority, results in a difficult PTM to study in most conventional labs. Therefore, it is of 
great interest to develop more sensitive and global assays to be able to more fully 
elucidate the breadth of the O-GlcNAcylation of the proteome.  
Kinases represent an intriguing group of proteins to first study as their cross-talk 
with OGT and OGA have been shown to be extensive (Wang et al., 2008). Inhibition of 
GSK3β has been shown to increase O-GlcNAcylation of many cytoskeletal and heat 
shock proteins, and decrease in transcription factors and RNA-binding proteins (Wang et 
al., 2007). Dysregulation of O-GlcNAcylation/phosphorylation appears to be important in 
the pathologies of diabetes and Alzheimer’s, as well as certain cancers (Dias et al., 2007, 
Kawauchi et al., 2009). Because of this, have a greater understanding of how the kinome 
is affected by OGT is of great importance.  
The difficulty in detection of O-GlcNAcylated proteins, coupled with the obvious 
importance of the modification on the kinome, led us to develop a novel way to quickly 
and specifically identify OGT substrates. Here, we show that through the use of both 
antibody and click chemistry techniques on kinome arrays, we were able to generate a 
high confidence list of O-GlcNAcylated kinases.  
Utilizing the two GlcNAc detection antibodies RL2 and CTD110.6 allowed us to 
detect in vitro O-GlcNAcylation on dozens of kinases. The specificity of our assay was 
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exhibited through competition using free GlcNAc during antibody binding, causing a 
dramatic decrease in observed signal. Also, treatment with the OGA homolog 
Clostridium perfringens NagJ (CpNagJ) abolished signal as well, further validating our 
method. Treatment of arrays with OGT after CpNagJ treatment was also able to rescue 
many of the hits we initially observed.  
A novel click chemistry approach was applied to the microarrays, which 
concurrently labeled O-GlcNAc residues with an additional azide sugar moiety that could 
react specifically with a copper-free fluorescent dye (Figure 3.4). Combining hits from all 
three methods allowed us to arrive at a high confidence hit list containing 104 kinases 
that were all hit in 2 replicates using each detection method.  
Several kinases were validated in vitro which allowed us to establish a threshold 
for our analysis. Among the hits shared by all three methods, 5 of 5 were validated in 
vitro. Similarly, among those with a less stringent cutoff (hit by 5 of the 6 assays 
performed), 7 of 9 were validated in vitro. Importantly, among the 4 hits below our 
threshold, none of them showed any signal in our in vitro assays (Figures 3.7 and 3.8). 
These results give us great confidence in the fidelity of our assay and points to a large 
contingent of the kinome (104/350; 30% of those tested using strict criteria) as being O-
GlcNAcylated.  
Gene Ontology analysis showed expected results given all hits were kinases, but 
also shared some characteristics with OGT including apoptosis, insulin signaling, and 
microtubule organization. Many other terms were enriched varying from stress and 
immune response to cell migration and wound healing. Given the apparent depth and 
 135 
variety of kinases in our final list, this is not surprising, and further studies are necessary 
to tease out this observation. 
Further validations were carried out in HeLa cells and all proteins tested showed 
O-GlcNAcylation after TMG treatment and FLAG immunoprecipitation (Figure 3.9). We 
were also able to identify O-GlyNAcylation sites on two proteins, BRSK2 (at S691) and 
PAK4 (at S12, S242, S243, and S267). Mutagenesis was performed on PAK4, and FLAG 
pulldown confirmed the identity of these sites. Therefore, we are very confident in the list 
that we have generated regarding the O-GlcNAcylation of the kinome as we have gone 
from chip, to test tube, to cellular, to site-specific identification of O-GlcNAcylation. 
Importantly, our final list was arrived using very strict criteria, as each hit had to be 
identified a total of 6 times across 3 detection methods. We were also able to validate a 
large percentage of kinases that showed signal even when only 5 of 6 arrays showed 
signal. Therefore, although our threshold is harsh, many other kinases that didn’t make 
the final cut indeed may (and are, as is the case with BRSK2) still be O-GlcNAcylated.  
This study represents a promising jumping off point for both the field of O-
GlcNAcylation and proteomics, as we have established a novel 3-pronged, high 
sensitivity microarray approach for the identification of O-GlcNAcylated proteins on 
protein microarrays. Further studies will be able to expand the scope of the assay to more 





3.9 Materials and Methods 
Protein Microarray Fabrication 
 Kinases were cultured in a high throughput manner (16 mL cultures) and purified 
as described before (Jeong et al., 2012) but also in the presence of Phosphatase Inhibitor 
Cocktails 2 and 3 (Sigma) to maintain kinase activity. After elution, proteins were re-
arrayed into a 384-well plate and printed using a split pin on a BIO-RAD VersArray 
ChipWriter Pro System.  
In vitro O-GlcNAcylation Assay 
 10x Calf Intestinal Alkaline Phosphatase (CIP; New England Biolabs, M0290S) 
was diluted into either 50 mM HEPES (pH 7.5) or 50 mM Tris-HCl (pH7.5) to make a 1x 
solution. Reaction mix was made by mixing 1L (1 Unit) of 1x CIP, 1 g ncOGT (up to 
3 g), 1 L of 250 nM 5’-AMP (SIGMA, A2252), 1 L of 200 mM UDP-GlcNAc (10 
mM Final Concentration; SIGMA, U4375) diluted up to 120 L/array. The negative 
controls contained everything but the ncOGT. Arrays were blocked for 1 hour at room 
temperature in 3% BSA in TBST and washed 3 times for 10 minutes in TBST. Excess 
buffer was wicked off of the arrays onto a kimwipe. 120 L of reaction mix was added to 
each array and a coverslip was carefully placed on top of the slide, making sure to avoid 
bubbles. Arrays were placed in a humidity chamber for 2 hours at room temperature. 
After labeling, the arrays were quickly immersed in 400 mL of TBST to remove the 
coverslips and were washed 3 times for 10 minutes in TBST before the next step. 
 This same general protocol was used for the validation studies in test tubes. 
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Antibody Binding Protocol (RL2 and CTD110.6) 
 After OGT labeling and washes, microarrays were treated with 120 L of 
antibody solution diluted in 3% BSA in TBST. Both Cy5-RL2 and Cy5-CTD110.6 were 
purified in the Hart lab for use on all of these experiments. For RL2 binding, a final 
concentration of 20 ng/L was used. For CTD110.6 binding, a final concentration of 5 
ng/L was used.  
 
Click Chemistry Labeling Protocol 
 Note: slides used for click chemistry experiments were epoxide slides, not 
FullMoon slides. Blocking was also performed using SuperBlock (Thermo) for 1 hour at 
room temperature. After OGT labeling and washes, arrays were labeled with the azide 
sugar GalNaz by GalT1 from the Click-iT
TM
 O-GlcNAc Enzymatic Labeling System 
(Invitrogen, C33368) overnight at 4° C. After wash steps, arrays were incubated with 
Alexa Fluor® 647 DIBO alkyne (Invitrogen, C10408) for 2 hours at room temperature.  
 
CpNagJ Treatment 
 CpNAgJ was diluted to a final concentration of 50ng/L in TBS before the 
addition of 120 L to each array followed by coverslip addition and placement in a 
humidity chamber. Arrays were incubated at 37° C for 2 hours before washes and 
treatment with antibody. Purified CpNAgJ was generously provided by the van Aalten 
lab (Rao et al., 2006).  




Mass Spectrometry Preparation 
 Recombinant proteins (GST-PAK4 or GST-BRSK2, 2μg) were purified from 
yeast as GST-fusion proteins. The eluates were then diluted with 2μL 500mM HEPES 
(pH 7.5) to 50mM HEPES (pH 7.5). One Unit of Alkaline Phosphatase CIP, 1μg ncOGT, 
and 1μL of 200 mM UDP-GlcNAc were added to solution to make the final volume of 20 
μl. The recombinant protein was in-vitro labeled with ncOGT for 2 hours at room 
temperature. After the reaction, the solution was further diluted with 6μL of 4x laemmli 
(gel loading) buffer and separated on 10% Tris-HCl Precast Gel (Bio-rad) before staining 
with Coomassie Bright Blue R-250. Individual gel bands were cut out and destained with 
100 mM ammonium bicarbonate buffer, Acetonitrile (ACN) in buffer (1:1), and 100% 
ACN. The samples were dried, reduced with 10 mM DTT at 37 
o
C for 2 hours, and then 
incubated with 20 mM IAA at room temperature in darkness for 45 min. Protein were 
trypsin-digested overnight (40 ng) at 37
o
C in 25 mM ammonium bicarbonate. Peptides 
were sequentially extracted with 5% FA in 50% ACN twice, and finally with 100% ACN 
with sonication at each stage. The extracts from each individual gel band were pooled 
and dried by a vacuum concentrator. The dried peptide sample was dissolved in 0.1 % 
TFA and the sample was desalted with a C18 spin column (The Nest Group, Inc.).   
The desalted sample was analyzed using an LTQ-Orbitrap Elite mass 
spectrometer (Thermo Fisher Scientific) with electron transfer dissociation (ETD). The 
peptides in the sample were separated by C18 reverse phase column with nano-flow 
HPLC, then analyzed by LTQ-Orbitrap Elite mass spectrometer using a spray voltage of 
2 kV. The full MS scans were acquired in the FT analyzer with the following parameters: 
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resolution 60,000; mass scan range (m/z) 400.0-1800.0. The 7 HCD MS
2
 were performed 
on the top 7 ions in full MS, meanwhile, the ETD MS
2
 was triggered with the same 
parent ions as when the product ions (204.0866, O-GlcNAc oxonium ionscans) were 
detected in the HCD MS
2
. For both HCD and ETD MS
2
, Isolation Width: 3.00; 
Activation Time is 130.00 for ETD MS
2
 and 0.100 for HCD MS
2
.  For the Dynamic 
exclusion, Repeat Count, 1; Repeat Duration, 30.00; Exclusion List Size, 500; Exclusion 
Duration, 80.00. 
 The MS2 spectra were searched against a modified target-decoy database 
including the sequences of the individual target proteins and a decoy version of a small 
inhomogeneous protein database (Anal Chem. 2009, 81(14): 5794-805) using MASCOT 
with the following parameters: enzyme, trypsin (KR/P); enzyme limits, fully enzymatic 
(cleaves at both ends); precursor-ion mass tolerance, 50 ppm; fragment-ion mass 
tolerance, 0.8 Da; missed cleavages, 2; fixed modification, Carbamidomethyl (C); 
Variable modifications, HexNAc (S), HexNAc (T), Oxidation (M). All potential O-
GlcNAcylated peptide MS
2
 spectra were carefully manually validated to localize the O-
GlcNAcylation site. 
 
Cell Culturing, Pulldown, and Western Blots 
 HeLa cells were grown in a 6-well culture dish in standard DMEM with 10% FBS 
and Pen/Strep to approximately 85% confluency before transfection of 850 ng/kinase in 
pSG5-FLAG mammalian expression vector using PEI (2L PEI/g DNA). Media 
exchange was performed 24 hours after transfection. Cells were treated with 1M TMG 
for 4 hours 48 hours after transfection before lysis in cold lysis buffer (125 L/well). 
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Lysis Buffer components: 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1mM EDTA, 1% 
Triton X-100, cOmplete ULTRA EDTA-free protease inhibitor (Roche), with 1M TMG 
or 50 mM GlcNAc. 375 L of each lysate was incubated with 20 L of ANTI-FLAG® 
M2 Agarose Beads (Sigma) overnight at 4° C on a rotator. The next morning, beads were 
washed 4x with 300 L cold lysis buffer before elution with 2x loading buffer. Samples 
were boiled for 5 minutes before gel electrophoresis and wet western transfer. 
Membranes were blocked for 1 hour at room temperature with 5% milk in TBST and 
washed three times with TBST before overnight incubation with primary antibody (RL2 
– 1:2000; CTD110.6 – 1:10,000) diluted in 3% BSA in TBST. Blots were then washed 
with TBST three times before incubation with secondary HRP antibody diluted in 3% 
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Chapter 4: Outlook and Future Directions of Protein Microarray Technology 
 
4.1 Future Perspective 
 
 The development of the protein microarray over the past decade has led to large 
strides in our scientific knowledge.  Combining versatility and specificity with the high 
throughput nature of the technology allows many labs to study anything from protein 
binding interactions, to post-translational modifications, to biomarkers quickly and 
reproducibly.   
While some studies have identified protein modifications using MS/MS 
approaches and even protein microarrays (Newman et al., 2013), there is still a great deal 
left unknown about how an enzyme specifically targets its substrate.  Peptide arrays are 
one growing field with a promising outlook on motif identification.  Studies by Rothbart 
and Mah have utilized peptide arrays to identify histone modifications and PTM motifs 
(Rothbart et al., 2012; Mah et al., 2006).  The fabrication techniques still leave room for 
improvement, however, as using in vitro translated peptides is expensive and slow, and in 
situ array formation lacks in quality control.  In situ arrays have the most straightforward 
approach to improvement, but this subset of microarrays will still be a powerful tool for 
modification identification in the future.   
Although useful, to date, many studies have used microarrays with limited 
proteomic coverage, limiting the characterization of what is truly a “proteome” array.  
This is especially true in higher eukaryotes.  The Zhu laboratory has taken great strides in 
increasing this coverage with their human proteome array, which consists of over 17,000 
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full-length human proteins, and is the largest to date (Jeong et al., 2012).  Utilizing this 
array could lead to further understanding and deeper characterization of the many PTM 
that have been identified via MS/MS approaches.  It is believed that these technologies 
will widely be used in the identification of biomarkers as well.  Recent studies have 
focused more on infectious and autoimmune diseases, but can be greatly useful in the 
identification of cancer biomarkers, potentially leading to diagnostic and prognostic 
capabilities.  The human proteome array is the ideal array to use for this technique, as it 
currently is the most comprehensive way to screen for antigens.  Although large screens 
can be prohibitively expensive, using the two-phase strategy in the AIH study described 
earlier (Song et al., 2010) could be the approach used clinically to obtain the greatest 
results.  Using mammalian cell lysates on these arrays could also provide a more relevant 
pseudo-in vivo system, building upon the technique utilized by Merbl and Kirschner 
(2009).  The benefit of having reaction cofactors in the reaction mix cannot be 
overlooked, which should drastically reduce the number of false positives and false 
negatives that can plague typical studies.   
Perhaps the most exciting new application in the study of microarrays is the 
advent of SPR and OI-RD technologies.  While still in its infancy, many experiments can 
be imagined that utilize this technique.  One of the largest hurdles in using antibody 
arrays and in the identification of biomarkers is the dearth of specific commercial 
antibodies.  To date, there is no standard metric for antibody affinities used for 
commercially available antibodies, which always results in a series of optimization steps 
by each lab in order to determine the best conditions for a particular assay.  Using 
SPR/OI-RD approaches could easily be used to screen antibody affinities, and in turn, 
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create some sort of unified measurement of affinity.  These label-free approaches could 
also theoretically be used for large-scale drug screens, without compromising the binding 
efficiency through conjugation with fluorophores or other large molecules such as biotin.  
One of the largest benefits of these approaches, however, is the ability to measure these 
interactions in real-time.  That, coupled with the high throughput nature of microarrays, 
can provide a powerful system of measuring enzyme kinetics and dynamics, drastically 
increasing our knowledge of these interactions.   
While much work is still to be done in truly understanding our world, protein 
microarrays appear up to the task for large-scale proteomic studies.  No other system 
allows for the amount of sensitivity, versatility, and high throughput ability than a 
microarray.  It is our belief that the future of personalized medicine will also utilize this 
technology in one form or another, leading to better diagnosis and prognosis in many 
diseases.  As this technology continues to mature, we can look forward to all the new 
connections that will be made, for protein microarrays are truly a versatile tool for 
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      Program: Pharmacology, PhD candidate 
      Honors: 
 Appointed to teaching fellowship at Loyola University to teach Biology 
courses for three semesters 
 Chosen to participate in newly formed course “Introduction to Effective 
Instruction” 
 First Place Poster Session Award for exemplary research poster at 
Pharmacology research retreat 
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Geneva College, Beaver Falls PA (graduated May 2007) 
Major: Chemistry (ACS-certified) 
Minors: Biology, Math 
GPA:  3.984 (4.0 scale)  
Honors:  
 Graduated Magna Cum Laude 
 Member of Alpha Chi, a National Student Honor Society 
 Recipient of Trustee Scholarship and Alumnus Chemistry Scholarship 
 American Chemical Society Polymer Education Committee Award for 
Excellence in Organic Chemistry 
 Presidential Scholarship for outstanding academic performance 




Johns Hopkins University (Aug 2007-present) 
 Graduate Student in the Department of Pharmacology studying kinase 
interactions with protein microarrays 
The University of Akron (May 2006-Aug 2006) 
 REU Internship studying elastic properties of virus films 
Geneva College (Aug 2004- May 2005; Aug 2005-May 2006) 
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 Lab assistant for non-science major lab (incl. physics, biology, and 
chemistry) 
Geneva College (May 2004 – May 2005) 




My doctoral work has focused on using protein microarrays to identify novel 
interactions between kinases and their respective substrates.  Protein microarrays consist 
of thousands of proteins immobilized onto a solid surface in a grid-like pattern.  They 
allow for the parallel experimentation of thousands of proteins at once in a single array 
the size of a microscope slide.   
The first project is a collaboration with a bioinformatician, who predicted novel 
scaffolding proteins using protein-protein interaction databases.  Treatment of a 
microarray with a kinase in the presence of 
32
P-γ-ATP, and with and without a third 
“scaffold” protein, allows for the identification of kinase substrates that can only be 
phosphorylated in the presence of a third party protein (i.e., a scaffold).  Using the 
hypothesized scaffolds on human proteome microarrays (which contain over 17,000 
purified human proteins), we were able to identify a large number of proteins that met 
this condition.   
The second project examines the apparent cross-talk between phosphorylation (by 
kinases) and glycosylation (by the enzyme OGT).  O-linked glycosylation is a post-
translational modification that occurs on S/T residues, similar to phosphorylation.  Many 
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studies have shown that both phosphorylation and glycosylation can affect kinase activity 
and substrate specificity.  Using antibody and click chemistry approaches that recognize 
glycosylated S/T, we were able to examine the glycosylation of over 100 kinases using a 




 High throughput purification of proteins, including active kinases 
o Oversaw the purification of the entire yeast genome 
(approximately 6,300 proteins) 
 Microarray fabrication 
o Have created a “kinome” microarray containing 460 human 
kinases 
 Radiation Safety Officer in lab (October 2011 – present) 
o No infractions in this time 
 Tissue Culture  
o Maintained HEK293, HeLa, and NIH3T3 cell lines 
 Proficient in western blotting, siRNA knockdown, in vitro enzyme assays, 
radioisotope experiments, DNA cloning, microarray analysis, and high 
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